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Triple Negative Breast Cancer (TNBC) is generally more aggressive that other 
subtypes and shows early lymph node involvement. These cancers are characterized 
by the lack of expression of the estrogen receptor, progesterone receptor, and the 
epidermal growth factor receptor HER2/neu and, as such, don’t respond to endocrine 
therapies targeting hormone receptors, or therapies with monoclonal antibodies 
inhibiting downstream signaling of HER2/neu. Although they respond very well to 
neoadjuvant chemotherapy, patients often suffer from relapse and distant metastasis, 
coupled with resistance to chemotherapeutic drugs. In this study, we sought to 
identify pathways critical for resistance and apply pharmacological methods to 
sensitize cancer cells to chemotherapy. 
We generated Paclitaxel-resistant TNBC cell lines, as Paclitaxel is a 
chemotherapeutic agent often used in first line treatment of TNBC patients. The 
TNBC cell lines, SUM159PT and MB231, were exposed to increasing concentrations 
of Paclitaxel, subsequently, showed an approximately 1000-fold higher EC50 to 
Paclitaxel, compared to their parental chemo-sensitive counterparts. We then used a 
pharmacological approach to identify pathways which play an important role and 
whose inhibition can sensitize resistant cells. Using a kinase inhibitor screen with 180 
small molecule inhibitors targeting various kinases, we identified PKC-β inhibitors to 
play an important role in re-sensitization. Upon validation, we found that PKC-β 
inhibitors can successfully sensitize resistant TNBC cell lines to Paclitaxel, and 
treatment with the PKC-β inhibitor Enzastaurin resulted in resistant cells undergoing 
apoptosis in the presence of Paclitaxel. PKC-α inhibitors, on the other hand, were not 
able to induce such a phenotype.  
Paclitaxel induces cell death of cancer cells by stabilizing microtubules, which results 
in mitotic arrest and subsequent cell death of parental, chemo-sensitive cells. 
Paclitaxel-resistant cells, however, are able to surpass mitotic arrest in the presence of 
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Paclitaxel. Interestingly, treatment with Enzastaurin was able to restore mitotic arrest 
resulting apoptosis of the resistant cell lines. It has been shown that activation of the 
Spindle Assembly Checkpoint (SAC) is a crucial event in Paclitaxel-induced cell 
death, and one of the main players in this checkpoint is Aurora Kinase B. 
Interestingly, Aurora Kinase B expression levels correlate with Paclitaxel-sensitivity 
only in basal-like breast cancer cell lines but not in cell lines of the luminal subtype. 
As expected, we found that the resistant cell lines had lower basal levels of Aurora 
Kinase B as compared to the parental cell lines, even in the presence of Paclitaxel. 
However, treatment with Enzastaurin could restore Aurora Kinase B expression 
which resulted in mitotic arrest and subsequent cell death in the presence of 
Paclitaxel. As expected, knock-down of Aurora B inhibited cell death in the resistant 
cell lines upon combination treatment.  
Taken together, this study shows that the small molecule inhibitor Enzastaurin can 
successfully restore Paclitaxel-sensitivity in Paclitaxel-resistant TNBC cell lines. 
Enzastaurin has been well studied in clinical trials and shows low toxicity in patients, 
therefore using this inhibitor in combination with Paclitaxel is a potential therapeutic 
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1.1 Breast Cancer 
 
Breast cancer is the most common cancer among women (1 in 3 cancers diagnosed) 
and the second most common cause of cancer deaths. According to the American 
Cancer Society ACS (Cancer Facts & Figures 2015), it is estimated that in the United 
States 231,840 women will be diagnosed with invasive breast cancer and 40,730 
women will die from it in 2015. Breast cancer arises from ductal or lobular tissues 
and is confined to these two regions at the initial stage of development and is 
therefore termed in situ carcinoma. At this stage, the cancer is treatable (surgical 
removal) with highly positive outcomes. However, if it is not detected it becomes 
invasive and infiltrates surrounding tissue leading to cancers with aggressive 
phenotypes with a high rate of metastasis and poor outcome.  
In general, breast cancer is more common among women of older age, but most cases 
diagnosed in younger women (age 35 and below) are of high grade, estrogen receptor 
positive (Gonzalez-Angulo et al., 2005) and hereditary. About 40% of all familial 
breast cancer cases are caused by genetic predispositions from mutations in high 
penetrance genes such as BRCA1 and BRCA2, whereas as low prevalence genes like 
TP53, CHK2 or PTEN (Kenemans et al., 2008) account for the rest. Mammographic 
screening was introduced to women in order to detect breast cancers early on and 
improve outcome, but there is much controversy around this topic, since many studies 
achieved different results. Some studies reported a decrease in breast cancer mortality 
(Gotzsche and Olsen, 2000) with regular screening in randomized trials, whereas 
others claim that regular screening comes with such high cost (length bias, lead-time 
bias and over-diagnosis), that they are not justifiable (Berry, 2013).  
Breast cancers are very heterogenous with substantial morphological, pathological 
and genetic variation. Therefore, classifying them into different subtypes provides 
important implications for diagnosis and therapy. This can be done based on gene 
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expression profiles of different breast cancers, or based on their hormone receptor 
status. 
1.1.1 Molecular profiling – genetic classification of breast cancers 
 
Microarrays enable gene expression profiling of thousands of genes in different 
cancers and allow us to create molecular profiles of a tumor. Perou et al. examined 
the expression levels of 8,102 genes in 65 breast cancer samples and classified then 
into different intrinsic subtypes: Luminal, Basal-like, HER2+ and Normal breast 
(Perou et al., 2000). Later it was found that the Luminal subtype can be further 
divided into Luminal A and Luminal B. Luminal breast cancers are characterized by a 
high expression of hormone receptors and hormone receptor-associated genes, 
HER2+ cancers have a high expression of HER2 and a low expression of the estrogen 
receptor (ER), and are more likely of high grade. Basal-like cancers manifest with a 
high expression of basal epithelial genes, but low expression of ER and HER2, and 
generally come with poor prognosis.  
Notably, the most important clinical implication of breast cancer subtyping is for 
prognosis and treatment. To date, there are various genomic assays available for 
breast cancer, which give information on the type of cancer and the therapy which 
will be most beneficial. Such platforms include Oncotype DX®, MammaPrint® and 
Mammostrat®. Oncotype DX is a diagnostic test to estimate disease recurrence in 
breast cancer patients and if they will benefit from chemotherapy after surgery. It is 
for women with early stage, estrogen receptor (ER) positive breast cancer and takes 
into account the gene expression levels of 21 genes (16 cancer genes and 5 reference 
genes). It also calculates the recurrence risk for DCIS (Ductal Carcinoma In Situ). 
Clinical studies are still ongoing with Oncotype DX.  MammaPrint is based on the 
expression levels of 70 genes in the Amsterdam 70-gene breast cancer signature to 
calculate the risk if a patient will develop metastases if given chemotherapy. It has 
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been FDA-approved for early stage, lymph node negative, hormone receptor-positive 
or -negative breast cancer and is carried out on paraffin-embedded or fresh tumor 
samples. The Mammostrat test uses the score of 5 genes based on their expression 
levels and assigns patients into different risk groups (high, moderate, low) to measure 
their risk of recurrence. So far, only Oncotype DX has been included in the NCCN 
and ASCO treatment guidelines. 
1.1.2 Hormone receptor status – breast cancer subtypes 
 
Although gene expression profiling of breast cancer can be used for predicitive and 
prognostic purposes, it is still expensive and not widely available yet. Other than gene 
expression profiling, the status of two hormone receptors can also be used to 
distinguish different breast cancer subtypes. The different subtypes vary in the 
expression status of the estrogen receptor (ER) and progesterone receptor (PR), and 
the epidermal growth factor (EGF) receptor HER2/neu. Breast cancer can be 
classified into four different subtypes based on their receptor expression status:  
1. Luminal A: ER+ and/or PR+, HER2/neu- 
2. Luminal B: ER+ and/or PR+, HER2/neu+ 
3. HER2+: ER- and PR-, HER2/neu+ 
4. Triple Negative Breast Cancer (TNBC): ER-, PR- and HER2/neu- 
Out of these four, Luminal A is the most common subtype with 66.9%, followed by 
TNBC (18.8%), Luminal B (8.3%), and HER2/neu+ (6.0%) (Lund et al., 2010). 
Figure 1.1 shows the distribution of breast cancer subtypes in women diagnosed with 
breast cancer from 2003-2004 where information on receptor status was available at 
time of diagnosis. 
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Furthermore, incidence rates for TNBC were higher in black women compared to 
white women, and TNBC is more common among younger women (age 35 and 
below) (Carvalho et al., 2010).  
1.1.2.1 Therapeutic implications 
 
Subtyping breast cancer according to ER, PR and HER2/neu has therapeutic 
implications since endocrine therapies can be used to treat hormone receptor positive 
tumors and HER2/neu can be blocked with monoclonal antibodies. TNBC, on the 
other hand, does not respond to any endocrine therapies or treatment with monoclonal 
antibodies, and the predominant form of treatment to this day is chemotherapy. In 
general, hormone receptor positive patients have a higher rate of survival compared to 
patients lacking hormone receptor expression (Fisher et al., 1988, Crowe et al., 1991) 
and adjuvant hormonal/ chemotherapeutic treatment can further increase survival rate 
in these patients (Fisher et al., 2004). 
 
Figure 1.1 Distribution of breast cancer subtypes diagnosed in women in Atlanta (USA) 
from 2003-2004. Adapted from Lund et al. (Lund et al., 2010). 
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1.1.2.2 Endocrine therapy for hormone receptor positive breast cancer 
 
Estrogen receptor signaling plays an important role in the normal development and 
growth of the breast tissue. The crucial role of estrogen in breast cancer was 
discovered over 100 years ago, when mortality rates for breast cancer patients 
decreased after their ovaries had been removed. 
ER+ breast cancers are dependent on positive signaling from activated ERs and when 
this signaling is shut off, it can lead to reduction of hormone-dependent proliferation 
and cell death. The ER status can be seen as a biomarker for responsiveness to 
endocrine therapies. Therapies can either target ER signaling directly using pure 
antagonists and selective estrogen receptor modulators (SERMs), or indirectly using 
aromatase inhibitors (AIs) which block estrogen production.  
There are two estrogen receptors, ERα and ERβ, that share 56% similarity in ligand 
binding domains, and nearly identical DNA binding domains. However, they possess 
different gene expression profiles and only a minority of genes regulated by ERβ is 
also regulated by ERα. (Grober et al., 2011). ERβ expression is more dominant in 
mammary tissues. It is expressed in epithelial and stromal cells, while ERα 
expression is only found in a subset of epithelial cells. However, ERα is upegulated in 
a large number of breast cancers and is linked to prognosis and response to hormone 
therapy, in contrast to ERβ expression (Roger et al., 2001, Zhao et al., 2008). The 
most commonly used antagonist targeting ERα is Tamoxifen, which binds to the 
receptor without activating it. Tamoxifen is a selective estrogen receptor modulator as 
it can act as an agonist in other tissues, such as the endometrium. It is standard 
therapy for ER+ tumors in premenopausal women and on occasion used in 
postmenopausal women. In addition to Tamoxifen, AIs are also effective in treating 
ER+, early stage breast cancers (Harvey et al., 1999). The aromatase enzyme is 
needed to convert androgen to estrogen and inhibition of its activity inhibits estrogen 
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production in the ovaries, thereby starving ERs of estrogen. AIs, such as anastrozole 
and letrozole, have been approved for treatment of ER+ tumors in postmenopausal 
women.   
 
1.1.2.3 Treatment for HER2/neu+ breast cancers 
 
Patients diagnosed with HER2/neu+ breast cancer show low overall survival (OS) 
and relapse-free survival (RFS), and poor prognosis. Overexpression of HER2 leads 
to increased activation of the MAPK and PI3K/Akt pathways, which leads to 
increased cell proliferation and survival (Yarden and Sliwkowski, 2001). Many of 
these patients respond well to treatment with Tratuzumab (Herceptin) which is a 
humanized monoclonal antibody targeting the extracellular juxtamembrane domain 
IV of HER2. Trastuzumab leads to a decrease in HER2 signaling followed by 
inhibition of cell proliferation, while simultaneously inducing antibody-dependent 
cellular cytotoxicity (ADCC) as it can activate immune effector cells (natural killer 
cells) (Yamauchi et al., 2011, Spector and Blackwell, 2009). Furthermore, it can 
inhibit the MAPK and PI3K pathways and inhibit angiogenesis (Nahta, 2012).  
Despite it’s positive effects for patients with primary HER2+ breast cancer, many 
tumors show resistance to single-agent treatment with Trastuzumab with a low 
median survival of 9 months (Nahta, 2012). Trastuzumab in combination with 
chemotherapy in an adjuvant setting can increase disease-free survival for patients 
with early stage breast cancer (Romond et al., 2005). Metastatic breast cancer (MBC) 
also shows a low response rate of 12-34% to Trastuzumab treatment as a single agent. 
However, clinical trials have shown that combination treatment of Trastuzumab with 
chemotherapy (Paclitaxel or Docetaxel) can increase response rates and OS (Esteva et 
al., 2002). Similar effects were achieved when combined with other chemotherapeutic 
agents such as cisplatin, carboplatin or ionizing radiation (Slamon et al., 2001). 
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This thesis focuses on TNBC, so we will describe this subtype in more detail in the 
next part of the introduction.  
 
1.1.3 Triple Negative Breast Cancer 
 
TNBCs are more aggressive than other subtypes of breast cancer in terms of relapse 
rates, tumor grade, and lymph node involvement (Haffty et al., 2006). Moreover, less 
than 30% of patients diagnosed with metastatic TNBC have a 5 year survival rate due 
to the lack of effective targeted therapies (Dent et al., 2007).  
Approximately 70%-80% of all Basal-like breast cancers are also triple negative and 
more than 80% of TNBC are basal-like, therefore these 2 terms are often used 
interchangeably to describe the same breast cancer subtype (Weigelt et al., 2010). The 
group of TNBCs can also encompass tumors that are of : (1) the claudin-low subtype, 
which have a high percentage of cells that have stem-like properties and show 
features of EMT; (2) the interferon-rich subgroup which has better prognosis than 
TNBC tumors; and (3) the normal-like subgroup with a high content of normal and 
stromal cells (Sotiriou and Pusztai, 2009). In addition, approximately 20% of basal-
like tumors express ER or HER2/neu (Turner et al., 2010).  
Various immunohistochemical panels have been proposed to distinguish basal-like 
subtypes, such as: (1) lack of the ER, PR and HER2/neu (TNBC); (2) expression of at 
least one high molecular weight/basal cytokeratin (CK5/6, CK14, CK17); (3) lack of 
ER and HER2/neu expression together with the expression of CK5/6 and/or EGFR 
(Nielsen et al., 2004); (4) lack of ER, PR and HER2/neu expression together with 
expression of CK5/6 and/or EGFR (Cheang et al., 2008). Despite the presence of 
various different definitions of basal-like breast cancer, they have distinct clinical 
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presentation, histological features, response to chemotherapy, sites of distant relapse, 
and outcome.  
Even among TNBC cancers there is great heterogeneity. Lehmann et al. analyzed 
gene expression profiles of 587 TNBC breast cancer cases from 21 databases and 
performed clustering analysis (Lehmann et al., 2011). He found that, depending on 
the gene expression profiles, the TNBC cases could be further classified into six 
different subtypes, which are listed in the table below. 
 
Subtype Gene expression profile 
Basal-like 1 (BL-1) High in the expression of genes involved in cell cycle progression, 
cell division, and DNA damage response pathway 
Basal-like 2 (BL-2) High in the expression of genes involved in cell cycle progression, 
cell division, and growth factor signaling 
Immunomodulatory 
(IM) 
High in the expression of genes involved in immune processes and 
cell signaling 




High in the expression of genes involved in motility, extracellular 
matrix, and growth factor signaling 
Luminal androgen 
receptor (LAR) 





However, basal-like breast cancers and TNBC share many similarities in terms of 
clinical prognosis and therapeutic responses (Badve et al., 2011). These cancers show 
lymph node involvement, high rate of recurrence, and are biologically more 
aggressive (Thike et al., 2010). Interestingly, basal-like breast cancers respond well to 
neoadjuvant chemotherapy with higher pathological complete response (pCR) 
compared to other subtypes (Lin et al., 2010). However, rates of distant metastasis 
and recurrence are higher for these patients. 
Figure 1.2 Intrinsic subtypes of Triple Negative Breast Cancer  
Six subtypes of Triple Negative Breast Cancer based on gene expression profiling (Peddi et al., 
2012, Lehmann et al., 2011). 
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Although the overlap between basal-like breast cancer and TNBC is not complete, 
many papers still use these terms interchangeably. Therefore, I will summarize the 
findings for both in a collective manner.  
1.1.3.1 Cellular origin of TNBC 
 
The fact that basal-like breast cancer cells possess breast stem cell-like properties 
gives rise to the question whether these tumors arise from breast stem cells. To date 
there are many reports on the epithelial hierarchy in the human breast where an 
undifferentiated ER-/PR-/HER2/neu- mammary stem cell (MaSC), capable of self 
renewal and differentiation, gives rise two committed progenitors: the myoepithelial 
and luminal progenitors (Figure 1.3). The myoepithelial progenitor then gives rise to 
mature myoepithelial cells that surround the luminal epithelium and contact the 
basement membrane. The luminal progenitor can be ER- or ER+ and will give rise to 
mature ductal and alveolar cells which line the lumen of the mammary gland and are 
also ER- or ER+ (Lim et al., 2009). Two different cell surface markers can be used to 
identify different subpopulations of cells in the breast: CD49f and EpCAM. When 
performing FACS analysis on highly purified subpopulations of MasSC/bipotent cells 
(CD49f+/EpCAM-), committed luminal progenitors (CD49f+/EpCAM+) and mature 
ER+/luminal cells (CD49f-/EpCAM+), it was found that the gene signature of the 
luminal progenitors was very similar to the basal-like gene signature (Lim et al., 
2009). Together with the findings that BRCA1-mutated pre-neoplastic breast tissues, 
which have a >80% chance to develop into basal-like breast cancer, show an 
increased population of luminal progenitor cells, these findings suggest that the cell 
of origin of sporadic and BRCA1-mutated basal-like breast cancer is the luminal 








1.1.3.2 Treatment strategies 
 
Patients with TNBC do not benefit from endocrine therapies targeting ER and PR, or 
therapies using monoclonal antibodies to target HER2/neu, as they lack expression of 
these specific hormone and EGF receptors. The mainstay of treatment until now is 
surgery and chemotherapy, or a combination of both. Some newer studies have 
identified certain receptors which play a role in tumorigenesis and progression of 
TNBC, and which could be potential targets for targeted therapies. Such receptors are 
EGFR and c-Kit, where it was found that c-Kit is highly expressed in 31% of basal-
like tumors and 11% of non-basal-like tumors (Nielsen et al., 2004). Moreover, 66% 
of patients triple negative tumor cells and basal-like tumor cells have been shown to 
Figure 1.3 Model of the human mammary epithelial hierarchy linked to cancer subtype  
Subpopulations of normal breast tissue and potential cells of origin for the intrinsic subtypes; 
various breast cancer subtypes molecularly compared to subpopulations from normal breast 
tissue; defining expression patterns of luminal, mesenchymal or claudin-low, and basal-like 
cells (Prat and Perou, 2009).  
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express EGFR, suggesting a therapeutic role for targeting EGFR (Reis-Filho et al., 
2005). Despite the promising preclinical data, clinical studies combining cetuximab, 
an anti-EGFR antibody, with carboplatin in stage IV triple negative breast cancer 
patients, showed that less than 20% of patients showed inhibition of the EGFR 
pathway, suggesting alternative activation mechanisms (Carey et al., 2012).  
We will look closer into the therapies available for TNBC patients.  
Chemotherapy 
Anthracyclines Anthracyclines are the most common chemotherapeutic drugs used 
for the treatment of TNBC patients. These compounds intercalate between base pairs 
and inhibit DNA and RNA synthesis preventing replication. They also inhibit 
topoisomerase II, an enzyme involved in the relaxation of supercoiled DNA, leading 
to DNA double strand breaks, which leads to activation of the DNA damage response 
signaling cascade (Nitiss, 2009). If DNA repair fails, the cells will undergo apoptosis. 
More recent studies have found that anthracyclines also induce histone eviction from 
chromatin and subsequent deregulation of the DNA damage response and DNA repair 
(Pang et al., 2013). Many studies show that TNBC patients are sensitive to 
anthracycline-containing therapies. The clinical response to therapy containing 
doxorubicin (an anthracycline) and cyclophosphamide, was higher in TNBC patients 
compared with non-TNBC patients in terms of pCR, although overall outcome (OS 
and DMFS) was still worse in comparison with non-TNBC patients (Carey et al., 
2007).   
Taxanes TNBCs show a high rate of genomic instability, due to defective pathways, 
such as mutations in BRCA1 (discussed above), therefore, using Taxanes may benefit 
these patients. Taxanes are spindle poisons which stabilize microtubules, and it was 
found that TNBC and HER2/neu+ patients are more sensitive to doxorubicin and 
Paclitaxel when used in a neoadjuvant setting as compared to luminal- and normal-
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like breast cancer patients (Rouzier et al., 2005). The addition of Paclitaxel to 
cyclophosphamide and doxorubicin could also enhance DMFS and OS in node 
positive, as well as TNBC and HER2/neu+ patients (Hayes et al., 2007). Several 
studies show improved outcome for patients with the addition of a taxane to the 
standard chemotherapy routine. One study showed great benefit with the addition of 
docetaxel in TNBC patients receiving conventional 6 cycles of FEC (5-Fluorouracil, 
epirubicine, cyclophosphamide) (Martin et al., 2010), while another study found that 
weekly paclitaxel is much more effective than paclitaxel every 3 weeks (Sparano et 
al., 2008).  
Platinum agents The mechanism of action for platinum agents, such as carboplatin 
and cisplatin, is intra- and inter-strand cross-linking of double-stranded DNA, thereby 
preventing formation of the replication fork and production of double strand breaks. 
Because TNBCs often harbor BRCA1 mutations or silencing, the DNA repair 
cascade is not fully functional and the cells will undergo cell death (Hastak et al., 
2010). One study showed that neoadjuvant cisplatin as a single agent in TNBC 
patient showed a pCR of 22% (50% of patients had a partial response) (Silver et al., 
2010). Another study found that 9 out of 10 patients with BRCA1 mutations achieved 
pCR after neoadjuvant therapy with cisplatin (Byrski et al., 2009). Cisplatin 
sensitivity is mediated by a p63-dependent tumor survival pathway in TNBC cells 
(Leong et al., 2007) and, importantly, cisplatin yielded a higher pCR rate in patients 
with p63+ tumors (Rocca et al., 2008). In a meta-analysis of randomized-controlled 
trials of platinum agents for TNBC patients it was found that platinum-based 
therapies yielded significantly better response rates and pCR rates compared to 
therapies without platinum (Guan et al., 2015).  
Combination of platin with a taxane-based primary chemotherapy has also shown to 
be effective in patients with locally advanced breast cancer (Frasci et al., 2009). 
Neoadjuvant cisplatin combined with paclitaxel and epirubicin in a weekly schedule 
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led to a 65% pCR. Moreover, when cisplatin was used in combination with epirubicin 
and 5-Fluorouracil a complete clinical response of 88% was achieved (Sirohi et al., 
2008). Therefore, when patients show resistance or high toxicity to therapies with 
anthracyclines, platinum-based therapies are a good alternative.  
Targeted therapies 
PARP inhibitors Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in 
DNA repair. Upon single strand breaks, PARP is recruited and its activation leads to 
single strand repair. However, when PARP is inhibited, the repair system can no 
longer be activated, leading to a stalling of the replication fork. The stalled replication 
fork will collapse and induce a double strand break in the DNA, which can be 
repaired by homologous recombination (HR). If the replication restarts, then the cell 
will survive. In BRCA-deficient cells where homologous recombination is impaired, 
the double strand breaks cannot be repaired, subsequently leading to cell death 
(Livraghi and Garber, 2015).  
The rationale for using PARP inhibitors in the treatment of TNBC comes from the 
observations that breast cancers with mutated BRCA show impairments of the HR 
pathway (Tutt et al., 2005) and some sporadic TNBCs harbor BRCA1 mutations 
(Turner et al., 2004). Others lack BRCA1 mutations but may show genetic profiles 
that are similar to tumors arising in BRCA1 carriers (van Beers et al., 2005), often 
times because they have defective BRCA1 pathways. This is partly due to CpG island 
methylation of the BRCA1 promoter and subsequent deactivation. Promoter 
methylation of one allele is found in 11-14% of sporadic breast cancers (Jones and 
Baylin, 2002) and often the second allele is lost due to loss of heterozygosity (LOH). 
This leads to the absence of BRCA1 expression and an inhibition of the pathway.  
Phase I and II clinical trials revealed that treatment with PARP inhibitors lead to 
improved outcomes as monotherapy in breast cancers with BRCA1/2 mutation, as 
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well as in ovarian cancers, and pancreatic and prostate cancers with confirmed 
BRCA1/2 mutations (Fong et al., 2009, Kaufman et al., 2015). Even in combination 
therapy, PARP inhibitors showed promising results especially when given together 
with platin-based agents in BRCA-related breast cancers (Balmana et al., 2014). 
Moreover, there are randomized phase III studies ongoing to test PARP inhibitors vs. 
single agent chemotherapy in breast cancer patients with metastatic disease and 
BRCA1/2 germline mutations (https://clinicaltrials.gov/ct2/show/NCT01905592, 
https://clinicaltrials.gov/ct2/ 
show/NCT01945775, https://clinicaltrials.gov/ct2/show/NCT02163694).  
EGFR inhibitors EGFR is often over-expressed in TNBC, therefore it is one of the 
targets in treatment for these patients. However, the results have not been positive. In 
a more recent phase II randomized study, metastatic TNBC patients were treated with 
a chimeric monoclonal antibody targeting EGFR alone (cetuximab), or in 
combination with carboplatin (Carey et al., 2012), however, there were no significant 
differences in PFS and both treatment groups showed rapid disease progression. 
Despite these results, there are still phase I and II clinical trials ongoing with 
cetuximab in combination with cytotoxic agents in metastatic TNBC. 
VEGF inhibitors VEGF was found to be higher expressed in TNBC compared with 
non-TNBC tumors, and that therapy with a recombinant humanized monoclonal 
antibody targeting VEGF, bevacizumab, could cause tumor suppression (Yadav et al., 
2014). However, clinical trials were not conclusive. Although some trials showed 
improved outcome in terms of ORR and PFS when adding bevacizumab to Paclitaxel 
in first-line treatment for TNBC patients (Gray et al., 2009), or in addition with 
docetaxel where it lead to an improvement in PFS (Miles et al., 2010), trials for the 
use in second-line therapy for metastatic TNBC showed improved RR and PFS, but 
not OS (http://meetinglibrary.asco.org/content/78329-102). Moreover, patients 
receiving bevacizumab-based treatments in first-line treatment experienced high 
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toxicity, hence its approval has been withdrawn due to a modest risk-benefit ratio. 
There is still one ongoing trial using bevacizumab in combination with an 
anthracycline-taxane-based chemotherapy in TNBC patients (Gerber et al., 2013). 
Although 40.1% patients showed pCR with improved DFS, only long-term studies 
will show whether patients experience OS.  
Tyrosine kinase inhibitors Other inhibitors targeting various kinases, such as c-Kit 
and other tyrosine kinases are being validated. However, the effect of c-Kit inhibitors, 
such as imatinib, in patients with TNBC and basal-like tumors is not clear as there are 
problems with the specificity of the antibodies in immunohistochemical staining in 
patient samples. Tyrosine kinases are also over-expressed in breast cancer metastatic 
disease, however, the use of tyrosine kinase inhibitors proves to lead to more positive 
outcomes in HER2/neu+ breast cancer patients (Ryan et al., 2008). Regardless, 




Patients with basal-like and HER2/neu+ breast cancers respond well to neoadjuvant 
chemotherapy composed of paclitaxel- and doxorubicin-containing chemotherapeutic 
agents, as compared to patients with other subtypes of breast cancer, in terms of pCR 
(Rouzier et al., 2005). Despite high response rates, many of these patients undergo 
relapse. Indeed, a study found that when compared to non-TNBC patients, patients 
harboring TNBC tumors treated with neoadjuvant chemotherapy showed higher pCR 
rates, but decreased 3-year PFS and 3-year OS. Moreover, these patients suffered 
increased visceral metastasis and shorter post recurrence survival (Liedtke et al., 
2008). Despite having decreased survival rates in the first 3 to 5 years after diagnosis 
(Figure 1.4 (A)), patients with TNBC or basal-like tumors actually suffer less distant 
relapse after this time, as compared to patients with other breast cancer subtypes 
17 
 
(Figure 1.4 (B)) (Foulkes et al., 2010, Tischkowitz et al., 2007). 10 years after 
diagnosis, ER+ patients are more likely to suffer relapse than ER- patients.  
 
Recurrence is often due to and accompanied by chemo-resistance to conventional 
chemotherapeutic agents. Some cells survive chemotherapy and can survive long-
term and maintain cell viability and lead to recurrent tumors. We will discuss 







Figure 1.4 Survival after a diagnosis 
of breast cancer 
A. Survival rate of 3744 
patients according to 
subtype. 639 women with 
TNBC subtype were divided 
into 2 groups: those with and 
without basal markers 
(cytokeratin 5, EGFR). (Data 
from (Cheang et al., 2008)). 
 
B. Hazard rates for distant 
recurrence of TNBC and 
non-TNBC patients. (Data 
from (Dent et al., 2007). 
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1.2 Mitotic inhibitors 
 
Mitotic inhibitors prevent cells from undergoing mitosis by disrupting microtubules, 
which are the main components of the mitotic spindle. Microtubules are crucial for a 
normal cell division as they bind to the kinetochores of sister chromatids and ensure 
proper segregation and migration of chromosomes during anaphase. 
Microtubules are made up of α- and β-tubulin dimers which bind to GTP on the (+)-
end of the microtubules. Once bound, the GTP hydrolyzes to GDP through contact 
with the dimers. The stability of microtubules is dependent on whether the β-tubulin 
dimer binds to a GDP or GTP on the microtubule. Dimers which are bound to GTP 
lead to microtubule assembly, whereas dimers bound to GDP tend to fall apart. The 
dynamic stability/instability is therefore dependent on the GTP/GDP bound to 
microtubules. The binding of microtubules to kinetochores is closely monitored by 
the Spindle Assembly Checkpoint (SAC), a cell cycle surveillance pathway, which 
can forestall further cell cycle progression in case of any misalignment (Foley and 
Kapoor, 2013). During the cell cycle, microtubules are assembled from the 
centrosome and then bind to the chromosomes once they have aligned along the 
metaphase plate. When the cell has passed through the SAC, the microtubules are 
disassembled into single dimers again. Correct microtubule assembly and 
disassembly is a requirement for proper cell division.  
Mitotic inhibitors target microtubule dynamics, thereby disrupting cell division, and 
can either be microtubule-stabilizing or –destabilizing, depending on their effects on 
microtubule dynamics. Microtubule-destablizing agents inhibit microtubule 
polymerization and inhibit the formation of the mitotic spindle at high concentrations. 
Most of these agents bind to either of two domains on tubulin: the “vinca” domain 
(vinca alkaloids such as vinblastine, vincristine, vinorelbine) or the “colchicines” 
domain (colchicines and its analogs). Microtubule-stabilizing drugs, on the other 
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hand, stabilize microtubules at high concentrations and inhibit progression into the 
anaphase. Such drugs include taxanes (Paclitaxel and Docetaxel), the epothilones, and 
ixabepilone.  
1.2.1 Paclitaxel (Taxol®) 
 
Taxanes (complex diterpenes) are produced by plants of the genus Taxus (yews), 
while some are now being synthesized artificially. The two main groups of taxanes 
are Paclitaxel (Taxol®), which is derived from Taxus Brevifolia, and Docetaxel 
(Taxotere), which is a semisynthetic analogue of Taxol (extracted from Taxus 
Baccata (Fauzee, 2011). The empirical formula for Taxol is C47H51NO14, it has a 
molecular weight of 853.9 and is insoluble in water (highly lipophilic). 
The antitumor activity of Taxol was first confirmed in 1977 in a mouse model of 
melanoma B16, and subsequently in mammary, lung and colon tumors. In 1984, the 
National Cancer Institute (NCI) started a Phase I clinical trial of Taxol against various 
cancer types. In 1992 it was FDA approved for ovarian cancer and shortly after for 
use against breast cancer (Seidman, 1994). Since then, Taxol has been proven 
effective against a number of solid tumors, including ovarian cancer, lung cancer, 
breast cancer, colon cancer, sarcoma, multiple myeloma, AIDS-related Kaposi’s 
sarcoma, and acute leukemias (Kumar et al., 2010, Sparano et al., 2008, Gill et al., 
1999, Rowinsky et al., 1989). Moreover, the antitumor effect of Taxol is increased 
when it is used in combination with other chemotherapeutic drugs, such as 
doxorubicin and various anthracyclines (Sledge et al., 2003, Kaufman, 1999), or 
specific inhibitors, such as trastuzumab (Herceptin) in breast cancer (Klos et al., 





1.2.2 Mode of action 
 
All drugs targeting microtubules bind to the β-tubulin subunit, and they all have 
distinct binding sites, dependent on whether they stabilize or disrupt the microtubules. 
Taxol binds to the β-subunit on three different peptides: amino acids 1-31 (Rao et al., 
1994), 217-231 (Rao et al., 1995), and 277-293 (Rao et al., 1999). It binds to the 
microtubule (it cannot bind to single tubulin dimers such as colchicines and vinca 
alkaloids) and enables microtubule polymerization in the absence of GTP. In 
addition, it protects microtubules from destabilization (Orr et al., 2003). At low 
concentrations, Taxol suppresses microtubule dynamics since it does not bind to all 
available binding sites. At high concentrations, however, it reduces the number of 
tubulin dimers available to assemble microtubules by stabilizing microtubule 
polymers which leads to a mitotic arrest. 
At low concentrations, where only a small part of the Taxol-binding sites are 
occupied on the microtubules, it suppresses microtubule dynamics, whereas at high 
concentrations, it increases polymer mass and induces microtubule bundle formation, 
which has become a hallmark of Taxol binding (Schiff and Horwitz, 1980).  
1.2.3 Mitotic arrest 
 
Cancer cells are especially susceptible to treatment with Taxol as they undergo a 
rapid cell cycle.  
Microtubule stabilization leads to cell cycle arrest in the mitotic (M) phase. Cells 
trapped in the M phase can undergo different fates, depending on the type and 
concentration of drug used (Gascoigne and Taylor, 2009) and the strength of the SAC 
signaling (Rieder and Maiato, 2004). After a mitotic arrest, cells can divide 
unequally, undergo cell death during mitosis, or exit the mitotic arrest without 
division. However, if they exit without division, they can arrest in the interphase or 
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undergo apoptosis, or they can pass through the cell cycle, which leads to tetraploidy. 
The variation in response can also be seen among cells of the same origin. Gascoigne 
et al. have summarized the different cell fates after treatment with anti-mitotic drugs 




In a normal cell cycle, activation of the SAC will prevent Cyclin B1 degradation, 
which is a requirement for M phase exit. Cyclin B1 is a protein involved in the 
regulation of mitosis. Its level is highest during the mitotic phase and cells can only 
progress through this phase after Cyclin B1 degradation. It was found, that in 
mammalian cells treated with anti-mitotic drugs, despite SAC activation, Cyclin B1 is 
slowly degraded which enables cells to exit mitosis, this is also called “mitotic 
slippage” (Brito and Rieder, 2006). The different rates of Cyclin B1 degradation may 
explain the variation in response to mitotic arrest. Mammalian cells that have an 
activated SAC and do not exit mitosis will undergo a mitotic catastrophe. It has been 
shown that targeting Cyclin B1 sensitizes breast cancer cells to Taxol (Androic et al., 
Figure 1.5 Cell fate in response to anti-mitotic drug treatment  
Mitotic arrest after Paclitaxel treatment leads to chronic SAC activation and mitotic arrest, after 
which they undergo one of several fates. (Derived from (Gascoigne and Taylor, 2009)). 
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2008), presumably because they will enter mitotic slippage which is dependent on 
Cyclin B1 proteolysis (Brito et al., 2008). 
1.2.4 Mitotic catastrophe 
 
Until now, there is no clear cut definition of what a mitotic catastrophe really is. It 
has been described by some as an aberrant form of mitosis (Ianzini and Mackey, 
1997), or a delayed form of reproductive death (Waldman et al., 1996), but in most 
cases it will eventually lead to cell death. Many events can lead to a mitotic 
catastrophe such as DNA damage, ‘mitotic slippage”, or defects in mitosis, such as 
mitotic arrest. Cell death following mitotic arrest can be through apoptosis or 
necrosis.  
Apoptosis following mitotic arrest requires activation of the SAC and mitotic 
slippage (Tao et al., 2005). Although this relation is not entirely clear, it has been 
found that BUB1 mediates caspase-independent cell death after mitotic arrest and 
determines the cell’s fate (Niikura et al., 2007). BUB1 is bound to the kinetochores of 
sister chromatids during mitosis (with a peak in the G2/M phase) to ensure correct 
chromosome alignment and plays a major role in the formation and regulation of the 
SAC. Together with BUB1, there are 13 other proteins that play a role in the SAC 
(such as Aurora kinase B, MAD1, MAD2, BUBR1, BUB3 etc.). Aurora B is required 
for the activation of the SAC and cells which have been depleted of Aurora B, fail to 
undergo mitotic arrest, even in the presence of chromosome misalignment or 
detachment from microtubules (Hauf et al., 2003). Taxol treatment causes a reduction 
of inter-kinetochore tension due to microtubule stabilization and this leads to an 
increase of BUBR1 and BUB1 at the kinetochores (Gorbsky and Ricketts, 1993) and, 
moreover, Taxol-mediated mitotic arrest is dependent on Aurora B (Ditchfield et al., 
2003, Hauf et al., 2003) and the presence of MAD2 at kinetochores (Waters et al., 
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1998). Survivin plays an important role in the maintenance of SAC and Aurora B 
localization (Okada et al., 2004).  
Several studies have shown that Taxol-induced apoptosis is caspase-dependent, as 
shown in the human colon carcinoma cell line HCT116 (Llovera et al., 2012) and in 
the Non-Small Cell Lung Cancer cell line NCI-H460 (Huisman et al., 2002). One 
possible mechanism is the involvement of death receptors which activate Fas-
associated death domains and Caspase-8, leading to Bid cleavage and the disruption 
of mitochondria. This is similar to many other DNA-damaging agents which induce a 
caspase-dependent apoptotic response. It was found that wild-type p53, activated 
after DNA damage, can inhibit mitotic catastrophe (Roninson et al., 2001) and many 
tumor cells are deficient for wild-type p53, making them susceptible to mitotic 















Chemo-resistance is one of the major challenges in the treatment of TNBC patients, 
as chemotherapy is still the mainstay of treatment and recurrence rates with poor 
outcome are high. Recurrence following chemotherapy can be attributed to the fact 
that some cancer cells survive chemotherapy and are able to maintain viability and 
survive long-term by undergoing cellular senescence and autophagy, as compared to 
apoptosis. Cells undergoing senescence have exited the cell cycle and lost their 
proliferative capacity, however, they maintain viability and metabolic activity (Saab, 
2010). By exiting the cell cycle, these cells are protected from the cytotoxic effects of 
chemotherapeutic agents. Moreover, it has been found that the senescence pathway 
plays a role in breast carcinogenesis by promoting tumor progression through 
stimulation of the neighboring cells with the senescence-associated secretory 
phenotype (SASP) (Pare et al., 2013). It was found that senescent cells produce 
lactate which is implicated in the tumor-stroma co-evolution. Breast cancer patients 
with long-term survival were found to have lower levels of lactate in tumor biopsies 
as compared with patients that died of cancer recurrence (Cao et al., 2012). On the 
other hand, autophagy is a type II programmed cell death involved in cellular 
homeostasis and protein and organelle recycling (Nishida et al., 2008). Its role in cell 
survival/cell death is controversial: it can either be activated as part of the survival 
pathway, or as part of the cell death process. Its role in cancer is even more 
controversial where it has positive and negative effects on tumor cell survival (Notte 
et al., 2011, Mathew et al., 2007). It is dependent on the type of tumor, tumor stage 
and extent of the insult. Especially in TNBC cells compared to other breast cancer 
cells, expression of the autophagy-related microtubule-associated protein, beclin-1, 
light-chain (LC) 3A and LC3B, are high, with low expression in the stroma (Choi et 
al., 2013). Moreover, LC3A is associated with tumor progression and poor outcome 
in TNBC (Zhao et al., 2013). It was found that the effect of paclitaxel treatment can 
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be enhanced when inhibiting autophagy. Also, positive effects were seen after 
treatment with an autophagy inhibitor combined with ER stress aggravators in TNBC 
(Thomas et al., 2012).  
1.3.1 Cancer stem cells 
 
Chemo-resistance accounts for up to 90% of drug failures in patients with metastatic 
cancer (Longley and Johnston, 2005). There are theories which suggest that a certain 
population of cells survive chemotherapy, these are cells with properties similar to 
stem cells and are responsible for tumor initiation and recurrence. These cells have 
been called cancer stem cells (CSCs) (Dalerba et al., 2007a) as they have properties 
similar to normal stem cells such as self-renewal and differentiation. The first 
evidence of CSCs was reported in 1994 by Lapidot et al. in acute myelogenous 
leukemia (AML) where they found cell surface markers by which they could select 
for CSCs (CD34+ and CD38-) and, more importantly, these cells could give rise to 
leukemic growth in severe combined immunodeficiency (SCID) mice (Lapidot et al., 
1994). CSCs of different origin express different cell surface markers and it was 
discovered that breast cancer tumor-initiating CSCs are ESA+/CD44+/CD24-/low. Cells 
selected based on these markers are capable of self renewal and differentiation (Al-
Hajj et al., 2003). Since then various CSCs populations in different solid tumors have 
been identified based on cell surface markers such as CD133, EpCAM and CD90, as 
well as aldehyde dehydrogenase (ALDH) activity (Yang et al., 2008, Dalerba et al., 
2007b, Singh et al., 2003).  
CSCs have been linked to tumor expansion and relapse through their ability to escape 
chemotherapy treatment. Many studies suggest that CSCs have adopted various 
mechanisms of chemo-resistance and, although there is an overlap between chemo-




1.3.2 Mechanisms of chemo-resistance 
 
Two mechanisms are thought to contribute to chemo-resistance: instrinsic and 
extrinsic resistance. Intrinsic resistance originates in the cancer cells itself which 
gives them the capability to withstand chemotherapy (Wilson et al., 2006), whereas 
extrinsic resistance is acquired by cells over a period of time via genetic and 
epigenetic mutations in genes as a result of chemotherapy treatment (Gillet and 
Gottesman, 2010). We will discuss some of the established mechanisms of chemo-
resistance in closer detail. 
Multidrug resistance The main mechanism of resistance is a high expression of 
membrane efflux pumps of the ATP binding cassette (ABC) family of transporters. 
The most important family member involved in drug resistance is the ABC subfamily 
B member 1 (ABCB1), also known as P-glycoprotein, or multidrug resistance protein 
1 (MDR1), which is capable of actively pumping Hoechst dye. It is a glycosylated 
membrane-associated enzyme which exports a number of different substrates. It has 
been found to be expressed in many different tissues such as liver, kidney, intestines, 
placenta and blood-brain-barrier, and hematologic and solid tumors. (Goldstein et al., 
1989). In the placenta and blood-brain-barrier its function is to protect from toxins, 
whereas in other tissues it functions as an efflux pump for xenobiotics, toxins and 
other drugs. In addition, ABCB1 transporters were found to be strongly expressed in 
the neurons of the hippocampus formation, and expression was further up-regulated 
upon induction of a status epilepticus in rat brains (Pardridge et al., 1997). In breast 
cancer, it was found that EGF could increase phosphorylation of ABCB1 to enhance 
multidrug resistance activity (Yang et al., 1997). 
More importantly, ABCB1 is also expresses in certain stem cells. Chaudhary and 
Robinson discovered that CD34+ hematopoietic stem cells show a high expression of 
ABCB1(Chaudhary and Roninson, 1991). One study used ABCB1-deficient mouse 
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models to study the function of ABC transporters and suggested that efflux pumping 
of xenobiotics which limits the success of chemotherapy may not be their only 
function. One of their main functions is a protection from apoptosis of stem cells. 
ABCB1 induces a stress-induced regeneration genetic program in normal tissues and 
is activated in cancer cells due to cancer therapy (Israeli et al., 2005). 
These results reveal an association between ABCB1 expression and stem cells, and, 
in addition, between ABCB1 and cancer cells. This suggests that high ABCB1 
expression could be linked to CSCs and also to chemo-resistance, as these 
transporters can efflux vincas and taxances, effectively reducing their intracellular 
drug concentration (Fojo and Menefee, 2005). In 1982, 6 years after the first link 
between ABCB1 and chemo-resistance was established, many compounds were 
developed which could inhibit ABCB1 and restore chemo-sensitivity in vitro. Despite 
some promising results with cancer cells and tissue, they proved ineffective in clinical 
trials due to many different reasons: low selectivity for ABCB1; poor potency; high 
toxicity; and diverse interactions with other anticancer drugs (Crowley et al., 2010).  
Another ABC transporter with importance in chemo-resistance is ABCG2. It was 
found to be especially highly expressed in progenitor cells/reactive ductules in the 
human liver, with a possible function of protection from cytotoxic agents (Borst and 
Elferink, 2002). It is often associated with ABCB1 as it has very similar functions in 
terms if efflux pumping of cytotoxic compounds, but in contrast to ABCB1 which 
characterizes proliferating cells, ABCG2 is believed to be a marker for quiescent cells 
(Ueda et al., 2005).  
Aldehyde dehydrogenase Another functional marker of CSCs which confers 
resistance to chemotherapeutics is Aldehyde dehydrogenase (ALDH). ALDH1 is a 
cytosolic enzyme which oxidizes aldehydes and converts them into carboxylic acids 
(Ikawa et al., 1983). There are 16 different ALDH isoforms and each isoforms has 
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specific functions in different types of cancer. ALDH1A3 has been found to be 
significantly associated with distant metastasis, disease-free survival and overall 
survival in breast cancer patients (Qiu et al., 2014). Since ALDH has been linked to 
normal stem and progenitor cells, its role in CSCs has also been extensively studied. 
Acute myeloid leukemic cells with elevated ALDH engraft better in NOD/SCID mice 
compared to cells with low ALDH activity (Cheung et al., 2007). And as little as 20 
breast cancer cells selected with an ALDH marker together with CD24-/CD44+ 
markers could form tumors (Ginestier et al., 2007).  
In addition to its function in CSCs, ALDH plays a role in chemo-resistance. 
Resistance to cyclophosphamide, a chemotherapeutic agent often used in first-line 
treatment for TNBC patients, is accompanied by high levels of ALDH and could be 
reversed by inhibition of ALDH in cyclophosphamide-resistant L1210 leukemic cell 
lines (Hilton, 1984). It has since then been shown to be important in 
cyclophosphamide-resistance in medulloblastoma (Friedman et al., 1992) and other 
cancer systems, thereby confirming the importance of ALDH in chemo-resistance and 
CSCs (Sreerama and Sladek, 1997). ALDH1A1 activity is also linked to gemcitabine-
resistance in human pancreatic adenocarcinoma. Ongoing studies with inhibitors 
targeting ALDH activity or influencing ALDH expression can help to overcome 
chemo-resistance in CSCs (Sullivan et al., 2010, Cortes-Dericks et al., 2014, Hellsten 
et al., 2011). ALDH is an established marker for chemo-resistance, although its exact 
function is not clear (Januchowski et al., 2013).  
We will discuss mechanisms of resistance to microtubule-disrupting drugs more in 






1.3.3 Resistance to microtubule disrupting drugs 
 
It is important to understand the specific mechanism of resistance to such agents in 
order to overcome and develop new and more effective drugs. Resistance can be the 
result of changes in the pharmacodynamics of these microtubule-disrupting agents 
such as cellular efflux and metabolization, ineffective target interaction, and 
resistance to apoptotic signals.  
Alterations in microtubules Changes in the targets of microtubule-disrupting agents 
contribute to resistance. Such changes can include changes in the conformation of 
tubulin dimers/microtubules so that the drugs are unable to bind, and changes in the 
GTPase activity needed for the synthesis of microtubules. Many proteins play a role 
in microtubule dynamics and can contribute to resistance through alterations in their 
expression levels, cellular localization, and post-translational modifications. These 
include various microtubule-associated proteins (MAPs) (MAP1, MAP2, MAP4, tau, 
STOP), and others like survivin which counteracts the effect of microtubule 
destabilizing agents (Cheung et al., 2009), FHit which interacts with microtubules 
and acts as a tumor suppressor (Chaudhuri et al., 1999) and stathmin which alters 
drug binding and inhibits progression into the M-phase (Cheung et al., 2009). Low 
expression of protein tau, which has the same tubulin binding site as Paclitaxel, is 
associated with Paclitaxel-sensitivity, as seen in preclinical studies. Similarly, high 
tau expression in ER+ breast cancer confers resistance to taxane-based chemotherapy 
and sensitivity to hormone therapy (Smoter et al., 2011).  
There are 13 different α- and β-tubulin isotypes involved in building of microtubules. 
The composition of the microtubules and the types of tubulin involved play a role in 
resistance. β-tubulin III has been shown to be associated with reduced taxane 
sensitivity in several types of tumors including lung, breast and ovarian cancers (Seve 
and Dumontet, 2008), and taxane-resistance has been attributed to increased levels of 
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βII and βV tubulins (Bhattacharya and Cabral, 2009, Haber et al., 1995). 
Interestingly, resistance to taxanes is not the only role for β-tubulin III. It is also a 
survival factor which can increase cancer progression independent of drug treatments 
in lung cancer (McCarroll et al., 2010). 
In addition to altered expression of tubulin, somatic mutations in β-tubulin also 
contribute to taxane resistance. In paclitaxel-resistant ovarian cancer cell lines, 
mutations at nucleotides 810 and 1092 of the HM40 isotype of β-tubulin lead to 
impaired paclitaxel-driven polymerization (Giannakakou et al., 1997). 
Resistance to apoptotic signaling Signaling downstream of microtubules also plays a 
role in resistance. P53 is involved in a complex mechanism which was believed to 
play a crucial role due to the fact that it can arrest the cell cycle and allow DNA 
repair. It was observed that by inactivating p53, normal and human murine fibroblasts 
could be sensitized to taxol (Wahl et al., 1996). However, it was later observed that 
more often than not, mutant p53 lead to drug resistance to various agents due to a 
disabled apoptotic machinery (Delia et al., 1996, Varna et al., 2009). In contrast, it 
was later published that p53 is not involved in resistance to Paclitaxel or Docetaxel in 
breast cancer (Noguchi, 2006). These conflicting results regarding the involvement of 
p53 in resistance render it an ineffective marker for taxane resistance.  
Apart from p53, other apoptotic regulators can influence taxane sensitivity. One such 
effector is the pro-survival protein B-cell lymphoma-extra large (Bcl-XL). Using a 
small molecule inhibitor targeting Bcl-XL, the cytotoxic effects of various 
chemotherapeutic agents, including Paclitaxel, could be enhanced in a NSCLC cell 
line (Shoemaker et al., 2006). In addition, certain microRNAs were also shown to 
play a role. One such example is of miR-125b which could confer resistance to 
Paclitaxel through suppression of the activity of the pro-apoptotic BAK1 in various 
breast cancer cell lines (Zhou et al., 2010). Another microRNA with a role in 
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resistance is miR-148a, which sensitizes prostate cancer cell lines to Paclitaxel by 
inhibiting the expression of mitogen and stress-activated protein kinase (MSK1) 
(Fujita et al., 2010).  
Resistance to other oncogenic signaling pathways Since chemo-resistance plays a 
major role in the treatment of TNBC patients, many studies have been conducted to 
unravel the importance of various pathways in conferring resistance. One such 
pathway found to play a role in resistance to Taxol is the Hippo pathway.  TAZ 
(transcriptional co-activator with PDZ-binding motif) is a major component of the 
Hippo-LATS pathway and has been found to be elevated in human breast cancer cells 
and responsible for Taxol resistance (Lai et al., 2011). TAZ activates the 
Cyr61/CTGF signaling pathway which modifies the Taxol response in breast cancer 





1.4 Aurora Kinase Signaling 
 
The Aurora Kinases are a family of evolutionary conserved serine/threonine kinases 
that play an important role and regulate many processes during cell division. They 
control the centrosome and nuclear cycles, they play crucial roles in chromosome 
condensation, spindle dynamics, kinetochore-microtubule interactions, chromosome 
orientation, and establishment of the metaphase plate. There are three Aurora 
Kinases, Aurora A, B and C, that are very similar especially in the carboxy-terminal 
catalytic domain, but they differ in the length and sequence of their amino-terminal 
(Figure 1.6). All three kinases have an activating T-loop, a destruction box (D-box) 
which leads to its destruction at the end of mitosis, and in addition Aurora A requires 





1.4.1 Aurora Kinases in cell cycle 
 
Interestingly, the three Aurora kinases have distinct functions and subcellular 
locations despite their similarities. While Aurora A associates with the spindle poles 
during cell division regulating mitotic entry, centrosome maturation and separation, 
and spindle pole polarity, Aurora B is an important member of the Chromosomal 
Figure 1.6 Schematic representation of human Aurora A, B and C  
The numbers indicate their size in terms of amino acids and their percentage of sequence 
identities. Also shown are the kinase domain (green), the activating T-loops (yellow), the 
destruction box (D-box, blue) and the D-box activating domain (DAD, red). (Figure adopted 




Passenger Complex (CPC) together with INCENP, Survivin and Borealin/DasraB. It 
localizes to the chromosomal centromeres during mitotic entry but will relocate to the 
microtubules at the spindle equator during anaphase. When the cell undergoes 
cytokineses, Aurora B accumulates at the spindle midzone and the cell cortex at the 
cleavage furrow, and subsequently concentrates at the midbody. In addition, Aurora 
B plays a crucial role for correct chromosome alignment and segregation, it regulates 
the kinetochore function. Moreover, it is required for correct spindle checkpoint 
function and cytokinesis.  
Equally important for cell division, is Polo-like kinase 1 (PLK1), one of the five 
members of the Polo-like kinase family. Inhibitors of PLK1 lead to mitotic arrest with 
a monopolar or disorganized spindle, and the cells will eventually undergo mitotic 
arrest (Steegmaier et al., 2007). All Polo-like kinases possess a highly conserved 
polo-box domain (PBD) in the carboxy-terminal end, which can serve as a docking-
motif that brings the kinase into close proximity of its substrates (Park et al., 2010). 
PLK1 can bind its substrates in a phospho-independent manner (Archambault et al., 
2008), or after it has undergone a priming phosphorylation by Cyclin-dependent 
kinase 1 (CDK1) or PLK1 itself (Elia et al., 2003). Once bound, the substrates will 
recruit PLK1 to the centrosome, kinetochore or the spindle midzone. It is not 
completely clear how it regulates spindle formation, but it is well known that PLK1 
plays a role in centrosome maturation and stable kinetochore-microtubule 
attachments (Archambault and Glover, 2009). The effect of PLK1 inhibition is 
similar to inhibition of the Aurora kinases, suggesting that they might co-regulate 
certain mitotic processes. PLK1 and Aurora A play a crucial role in mitotic entry. 
They co-localize at the centrosomes, but then PLK1 also localizes to kinetochores in 
the prometa- and metaphase. Aurora B, however, is important in the prophase where 
it localizes to the arms of the chromosome and the inner centromere, whereas in the 
prometa- and metaphases it localizes solely to the inner centromeres. Aurora B co-
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localizes with PLK1 on the central spindle, the cortex and midbody in the anaphase 
and telophase where they regulate cytokinesis. Aurora A is degraded in the anaphase 
and telophase, although a small portion remains at the central spindle and midbody, 





Figure 1.7 Localization of 
Aurora kinase A and B 
together with PLK1 in the 
dividing cell  
Aurora kinase B is localized 
to the chromosome arms and 
inner centromere in the 
prophase, whereas in the 
prometaphase and metaphase 
it is only found at the inner 
centromere. In anaphase and 
telophase it co-localizes with 
PLK1 on the central spindle, 
cortex and midbody where it 
regulates cytokinesis. (Figure 
adopted from Lens S.M.A. et 






1.4.2 The Spindle Assembly Checkpoint 
 
Aurora B, along with the CPC, stabilizes the mitotic spindle (Gassmann et al., 2004) 
by phosphorylating Stathmin/Op18 and the kinsein-13 microtubule-destabilizing 
protein (MCAK), two proteins involved in the chromatin-driven spindle assembly 
pathway (Ohi et al., 2004, Gadea and Ruderman, 2006).  
The main components of the spindle assembly checkpoint (SAC) are MAD1, MAD2, 
BUBR1, BUB1, BUB3, MPS1, and Aurora B, and it is activated during cell division 
where it inhibits anaphase as long as the kinetochores are not attached to the 
microtubules. Only when all kinetochores are stably bound, the SAC is satisfied and 
inhibition of the anaphase is alleviated. Three of the SAC proteins, MAD2, BUBR1 
and BUB3, as well as CDC20, make up the mitotic checkpoint complex (MCC), 
which binds the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C), 
inhibiting its ubiquitin ligase ability on securin and cyclin B (Tang et al., 2001, Fang 
et al., 1998). Securin is the inhibitor of a protease called separase which is required to 
cleave the cohesion complex which binds the sister chromatids, while cyclin B 
activates CDK1, inhibiting exit from mitotsis. CDC20 is a co-factor of APC/C and by 
keeping it in check, the SAC can prolong the prometaphase until all the kinetochores 
are attached to the microtubules and are bi-oriented along the metaphase plate. 
Aurora B plays an important role in the SAC as it regulates kinetochore assembly. 
Kinetochores are complex structures comprising of at least 80 different proteins at the 
centromere of each sister chromatid (Cheeseman and Desai, 2008, Santaguida and 
Musacchio, 2009), and they link the chromosomes to the microtubule polymers of the 
mitotic spindle. The inner kinetochore is tightly associated with the centrosome DNA 
throughout the cell cycle, whereas the outer kinetochore, which interacts with the 
microtubules, is a dynamic structure only present during cell division. For correct 
chromosome segregation, each sister chromatid has to attach to microtubules 
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generated from opposite spindle poles through its kinetochores. This is called a 
amphitelic configuration, or bi-orientation. If the kinetochores are not correctly 
attached, they can have a monotelic configuration (only one of the chromatids is 
attached to microtubules), syntelic configuration (both chromatids are attached to the 
same microtubule generated from one spindle pole), or a merotelic configuration (at 
least one chromatid is attached to both microtubules generated by opposite spindle 
poles). The role of Aurora B is to ensure correct kinetochore-microtubule attachments 
by destabilizing incorrect attachments. Correct amphitelic attachments are stabilized 
by tension through the mitotic spindles (Nicklas and Koch, 1969), whereby Aurora B 
is an important tension sensor at centromeres and kinetochores (Biggins and Murray, 
2001, Tanaka et al., 2002). Inhibition of Aurora B using small molecule inhibitors or 
inhibitory antibodies has been shown to stabilize incorrect attachments to a single 
spindle pole (Hauf et al., 2003). More recently, a “spatial separation” model has been 
proposed which explains how Aurora B is able to sense tension. In this model, 
tension sensing depends on the localization of Aurora B. When bi-oriented 
kinetochores are separated, Aurora B at the inner centromere is separated from its 
outer kinetochore substrates (Tanaka et al., 2002). 
Several mechanisms contribute to the deactivation of the SAC. During the process of 
“stripping”, MAD1 and MAD2 are removed from the kinetochores and this seems to 
be a crucial step in deactivation (Maldonado and Kapoor, 2011). This process is 
mediated by the minus-end microtubule motor dynein (Howell et al., 2001). Also 
important is the disassembly of the inhibitory complexes in order to free Cdc20 so 
that it can activate APC/C, thereby allowing it to ubiquinitylate securin and cyclin B, 





1.4.3 Paclitaxel-induced activation of the SAC 
 
Paclitaxel stabilizes microtubules, thereby reducing the tension on the kinetochores 
from mitotic spindles in bi-oriented sister chromatids. This process turns on the SAC 
thereby stopping the progression of the cell cycle. Moreover, it was found that MAD2 
is required to maintain taxol-mediated mitotic arrest (Shannon et al., 2002). CENP-E 
is a microtubule plus-end-directed motor that is crucial for chromosome alignment 
and when CENP-E is absent, unattached kinetochores are unable to sustain SAC 
activity. However, the addition of taxol disrupts tension and can override CENP-E 
absence and activate SAC activity (Wood et al., 2008). However, siRNA knock-down 
experiments revealed that the absence of Aurora B compromised checkpoint arrest in 
the Paclitaxel-treated colon cancer cell line DLD1 (Ditchfield et al., 2003). Moreover, 
Aurora B knock-down also led to absence of microtubule-kinetochore interactions, 
suggesting that Aurora B plays role in correct kinetochore attachments. In addition to 
its role in destabilizing improper microtubule attachments, Aurora B also plays a 
direct role in the SAC.  
1.4.4 Aurora Kinases in Cancer 
 
It was discovered that Aurora A and Aurora B are over-expressed in primary breast 
cancer samples (Sen et al., 1997) and colon tumor samples (Warner et al., 2003), 
suggesting that they are associated with tumorigenesis. Aurora A is most consistently 
associated with cancer and its role is well studied. It has been found to be over-
expressed in many different kinds of cancer, such as colon, breast, bladder, liver, 
gastric and pancreatic cancer (Sakakura et al., 2001, Goepfert et al., 2002) and its 
over-expression is significantly associated with high grade tumors and poor prognosis 
(Jeng et al., 2004). There is a correlation between Aurora A over-expression and 
aneuploidy in gastric cancer. Aneuploidy is associated with poor outcome in a 
number of malignancies, and in gastric and papillary thyroid cancer it is a metastatic 
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marker (Sasaki et al., 1999, Sturgis et al., 1999). Aurora A over-expression is also 
associated with centrosome amplification which leads to bipolar mitotic spindle 
defects, chromosomal segregation deficiency and aneuploidy. Centrosomal 
abnormalities have been shown to arise in early stages of tumor development and 
expand as the tumor progresses (Pihan et al., 2001), especially in brain, breast, lung, 
colon and prostate cancer (Pihan et al., 1998, Lingle and Salisbury, 1999). However, 
so far no direct link has been found between Aurora A over-expression and 
centrosomal abnormalities, although they are often associated with each other.   
Aurora A has also been reported to play an important role in transformation. It 
phosphorylates and regulates the breast cancer-associated gene product BRCA1 
(Ouchi et al., 2004), and it can regulate telomerase activity through c-Myc in ovarian 
and breast epithelial carcinomas (Yang et al., 2004). Moreover, it interacts with p53 
at multiple levels. It directly phosphorylates p53 at Ser315 mediating degradation of 
p53 by MDM2 in cancer cells, and at Ser215 thereby inactivating its transcriptional 
activity (Katayama et al., 2004, Liu et al., 2004). TP53 is the most common gene 
mutated in a number of human cancers, whereby the most common mutations lead to 
a complete loss or inactivity of the p53 protein (Kandoth et al., 2013). This shows the 
importance of Aurora A in cancer, especially in transforming processes.  
Aurora B has been found to be over-expressed in cancers such as breast, kidney, 
colorectal, prostate and lung cancer, and high levels of Aurora B lead to multi-
nucleation and polyploidy in human cells (Tatsuka et al., 1998). Moreover, it was 
found that high levels of Aurora B correlate with late stages of colorectal cancer 
(Katayama et al., 1999). It may also play a role in carcinogenesis as high levels lead 
to chromosome lagging in the metaphase, errors in chromosome segregations and 
cytokinesis (Ota et al., 2002). Although Aurora B alone is not able to transform cells, 
it potentiates H-Ras(G12V)-induced transformation (Kanda et al., 2005). During 
mitosis, half of the Aurora B forms a complex with INCENP, Survivin and Borealin, 
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whereas the other half forms a complex with INCENP, but it is not clear which of 
these complexes is involved in the potentiation of oncogenic Ras.  
Aurora C, however, is a chromosome messenger protein and only expressed in the 
testis and not somatic cells. It has been found to be up-regulated in cancer cell lines 
such as HepG2, HuH7, MDA-MD-453 and HeLa cells, although its role is unclear 


















1.5 Protein Kinase C Signaling 
 
Protein Kinase C (PKC) has become an attractive target for drug discovery in the past 
20 years as it functions as the receptor for the tumor promoter phorbol ester 
(Castagna et al., 1982).  It has gained even more interest since it was discovered to 
play a role, not only in cancer, but also in other diseases such as diabetes, ischemic 
heart disease and hear failure, autoimmune diseases, Parkinson’s disease, 
Alzheimer’s and many other diseases.  
1.5.1 Structure and isoforms of PKCs 
 
PKC is a family of at least 12 highly related but distinct serine/threonine kinases 
which play a role in signaling pathways involved in proliferation, differentiation, 
angiogenesis and apoptosis, as well as transcription, translation, and cell-cell contact. 
The different isoforms can be grouped into 3 classes depending on the number of 
conserved regions (C1-C4) and the number of variable regions (V1-V5) (Khalil, 
2010). The C1 region contains cystein-rich zinc finger-like motifs and the recognition 
site for Diacylglycerol (DAG), phosphatidylserine and phorbol ester. The C2 region 
of some isoforms contains the binding site for Ca2+, and the C3 and C4 regions 
constitute the ATP- and substrate-binding lobes (Figure 1.8). Due to the PKC 
isoforms containing different conserved and variable regions, they are activated 
through different processes. The conventional PKC isoforms (α, βI, βII and γ) contain 
all conserved regions (C1-C4) and all variable regions (V1-V5) and can be activated 
by DAG, phoshatidylserine, phorbol ester and Ca2+. The novel PKCs (δ, ε, η and θ) 
lack the C2 region and are therefore not affected by Ca2+, and the atypical PKCs (ζ 
and λ/ι) have only one cysteine-rich zinc finger-like motif and can only be activated 
by phosphatidylserine. Phospholipase C (PLC) is an enzyme which, when activated 
by G-protein coupled receptors (GPCR), can generate DAG and 1,4,5-triphosphate 
(IP3) by hydrolyzing phosphatidylinositol-4,5-biphosphate (PIP2). IP3 then binds to 
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Ca2+positive channels on the endoplasmic reticulum which release Ca2+ into the 
cytoplasm. PKC can bind to Ca2+, translocate to the cell membrane and interact with 
DAG. A fourth class of PKCs, the PKN subfamily, is distinctly different to the 
previous 3 classes in that it has 3 tandem coiled motifs, known as HR1 domains, 






Due to their highly homologous kinase domains and variable regulatory domains, the 
PKC isoforms can activate a number of different cellular signaling pathways. 
Therefore, targeting this pathway remains challenging and the question to ask should 
not be “what” activity to target, but “where”. 
1.5.2 Activation of PKC isoforms and downstream signaling 
 
PKCs contain an autoinhibitory pseudosubstrate. When PKC is inactive, it is folded 
in such a way that its kinase region is bound to its own pseudosubstrate. Upon 
phosphorylation of serine/threonine residues by any of its activators, PKC can unfold 
and bind its true substrate. Stimulation of PLC increases the DAG levels at the 
Figure 1.8 Schematic sequence of Protein Kinase C (PKC) isozymes indicating the domain 
structure of the PKC subfamilies and their activators 
(Figure adopted from Cosentino-Gomes D. et al. (Cosentino-Gomes et al., 2012)). 
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plasma membrane, followed by the re-localization and activation of various PKC 
isoforms. There are some requirements for the activation of PKC isoforms: regulation 
of their intrinsic kinase domain activity through a priming phosphorylation of the 
activation loop by PDK1; and phosphorylation (or charged residues) at the 
hydrophobic sites within the C-terminal tail through mTORC2 (Facchinetti et al., 
2008, Ikenoue et al., 2008). Once activated, the C-terminal tail will fold back and 
occupy the hydrophobic pocket to stabilize the active conformation. A recently 
identified player in the activation of cPKCs and nPKCs is heat shock protein-90 
(HSP90) (Gould et al., 2009). In order for the PKCs to mature so that they can be 
phosphorylated by PDK1 and mTORC2, HSP90 and the co-chaperone Cdc37 need to 
bind to a molecular clamp in the kinase domain formed by a conserved PXXP motif 
in the carboxyl-terminal tail. If this binding is not possible, PKCs are unable to be 
phosphorylated and will be degraded. Once HSP90 and Cdc37 have bound, PKCs can 
be phosphorylated by PDK1, a step necessary for the processing of PKCs to their 
fully phosphorylated forms.  
When PKC binds to the membrane, it undergoes a conformational change to expose 
its kinase binding region (Newton, 2003) and can activate downstream signaling 
pathways, such as the MEK/ERK and PI3K/Akt (Cai et al., 1997, Balendran et al., 
2000). Different PKC isoforms show different subcellular localization depending on 
the tissue type. The Receptors for Inactivated Kinases (RICKs) and the Receptors for 
Activated Kinases (RACKs) bind PKC in an isozyme-specific manner and are 
responsible for the translocation of PKC to the different cellular compartments 
(Mochly-Rosen and Gordon, 1998). Phorbol esters can activate PKC by promoting its 
translocation to the cell membrane, and this effect can be inhibited by 
glycoglycerolipid analogues, which block its translocation and activation of the 
downstream signaling pathways MAPK and FAK, which are involved in adhesion, 
migration and proliferation (Colombo et al., 2011). Further downstream signaling of 
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PKC includes the modulation of membrane structure events, transcription regulation, 
receptor desensitization, and immune response (Nishizuka, 1992).  
It has been shown that the PKC isoforms α, βI and γ can phosphorylate GSK3β at 
Serine 9 and that this renders GSK3β inactive (Goode et al., 1992). This in turn 
inhibits the phosphorylation of c-Jun at its inhibitory phosphorylation site, thereby 
allowing it to interact with its DNA binding site. GSK3β therefore acts as a cytosolic 
bridge between PKC and c-Jun.  
1.5.3 PKCs in Cancer 
 
The discovery of the PKC activator, phorbol ester, has led to the belief that the 
activation of PKC can promote carcinogen-induced tumorigenesis (Griner and 
Kazanietz, 2007). It has functions related to cell survival, proliferation, invasion, 
migration, angiogenesis, apoptosis and drug resistance. However, targeting PKC has 
been unsuccessful so far as it is an unpredictable target. In some cancers it can act as 
an oncogene, whereas it can have tumor suppressing functions in others. PKC-δ, for 
example, can promote tumor progression in lung and pancreatic cancers under certain 
conditions (Symonds et al., 2011), whereas it can act as a tumor suppressor in many 
cell types (Reyland, 2007). In colon cancer cell lines, both loss and over-expression 
of PKC-ζ could decrease tumorigenocity (Ma et al., 2013, Luna-Ulloa et al., 2011); 
and PKC-α can induce (Wu et al., 2013) and suppress (Gwak et al., 2009) 
proliferation of colon cancer cells. Moreover, PKCs can promote apoptosis through 
different pathways. These include secretion of TNFα and TRAIL in prostate cancer 
cells by PKC-δ which triggers an autocrine apoptotic loop; induction of cytochrome c 
release and activation of Caspase 3 by PKC-δ in colon and prostate tumor-derived 
cell lines. On the other hand, PKC-δ can also confer resistance to apoptotic signals by 
activation of the Akt pathway and modulation of NF-κB-dependent gene expression 
(Diaz Bessone et al., 2011). PKCs not only affect apoptosis in cancer but also 
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migration, invasion and tumor promotion. Over-expression of PKC-α can lead to 
increased anchorage-independent growth, tumorigenicity and metastasis; over-
expression of PKC-βII enhances invasiveness through Ras and MEK signaling 
(Zhang et al., 2004). It has been shown that PKC is able to phosphorylate Raf-1, but 
this can only stimulate its autophosphorylation, not its activity towards MEK-1 
(Macdonald et al., 1993). However, some studies on prostate cancer have found that 
phosphorylation of PKC could inhibit the Raf Kinase Inhibitory Protein (RKIP) 
thereby increasing Raf-1 activity. Activation of this pathway is linked with metastasis 
in prostate cancer (Keller et al., 2004). 
Recently, Gong et al. found opposing roles for conventional and novel PKC isoforms 
in the activation and regulation of the Hippo-YAP pathway (Gong et al., 2015). This 
pathway plays an important role in development by modulating cell number, cell 
death and cell differentiation, and deregulation can be the cause for many types of 
cancer (Yu and Guan, 2013). Important players of the Hippo pathway are the MST1/2 
and LATS1/2 kinases, whereby LATS1/2 is phosphorylated by MST1/2. LATS1/2 
can then phosphorylate and inhibit the transcriptional co-activators YAP and TAZ. 
Moreover, it has been discovered that extracellular signals act through GPCRs to 
regulate the Hippo-YAP pathway, and PKC is one of the main downstream actors of 
GPCRs, linking the Hippo and PKC pathways. Interestingly, they found cell type-
specific roles for PKC in regulating the Hippo pathway. While the cPKCs can 
dephosphorylate and activate YAP, the nPKCs phosphorylate YAP, thereby 
inhibiting it. These effects occur through the activation/inhibition of LATS by the 
different isotypes.  
The diverse effects of PKC signaling on cancer cells could be the reason why PKC 
inhibitors have been ineffective in clinical trials. Zhang et al. recently reported the 
results of a meta-analysis of controlled trials using PKC inhibitors combined with 
chemotherapy or chemotherapy alone in patients with non-small cell lung cancer 
45 
 
(Zhang et al., 2015). They found that PKC inhibitors even decreased the response 
rates (RR 0.79) and disease control rates (RR 0.90) with no significant difference in 
progression free survival and overall survival. This raises the question of whether loss 
or over-expression of PKC isozymes can promote carcinogenesis and promote tumor 
progression. Although phorbol esters are tumor promoters and considered PKC 
activators, it is well known that chronic treatment of cells with Phorbol esters can 
deplete PKC isozymes, rather than lead to hyperactivation of the PKC signaling 
pathway. This might explain the unexpected results of clinical trials.  
1.5.4 PKC in Breast Cancer 
 
Various PKC isoforms are involved in normal mammary development, such as in the 
control and activation of mitogenic/apoptotic signaling. Their expression and 
localization are modulated during mammary gland development and differentiation. 
Moreover, an over-expression of PKC isoforms has been reported in breast tumors 
and breast cancer cell lines (Jarzabek et al., 2002). PKC-α, for example, has been 
found by some to be over-expressed in human breast cancer cells and tumor samples 
(Lahn et al., 2004), and others have found it to be down-regulated (Kerfoot et al., 
2004). Moreover, PKC-α was found to play a role in breast CSCs as its expression 
positively correlates with aggressive TNBC, and inhibiting PKC-α could specifically 
target CSCs with little effect on non-CSCs (Tam et al., 2013). Furthermore, PKC-α 
was shown to suppress c-Jun phosphorylation in ER+ breast cancer cells, leading to a 
down-regulation of ER-α expression. It is, therefore, a potential therapeutic target for 
treating ER+ Tamoxifen-resistant breast cancer (Kim et al., 2014).  
1.5.4. PKC-β 
 
PKC-β has two major splice variants: PKC-βI and PKC-βII. Although it has been 
found that both isoforms have slightly different functions, it is complicated to 
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interpret their roles since many early studies did not differentiate between the 
different splice variants.   
PKC-β has gained importance in breast cancer since the discovery of its role in 
angiogenesis, and breast cancer tumorigenesis in rodent models and humans. 
Especially in TNBC, the PKC-β inhibitor, LY379196, can inhibit growth of various 
TNBC cell lines in vitro (Li and Weinstein, 2006). Although PKC-β drives tumor 
growth and proliferation of cancer cells, over-expression can impair the tumorigenic 
and metastatic potential of tumor-derived murine mammary cell lines, suggesting an 
inhibitory role for PKC-β (Grossoni et al., 2009). In addition to growth inhibition, 
over-expression could also revert a transformed phenotype by leading to re-
expression of fibronectin and extracellular matrix glycoproteins.  
A recent study analyzed 8% of PKC mutations identified in human cancers and found 
that the majority of these mutations are loss-of-function mutations, rather than gain-
of-function mutations (Antal et al., 2015). Moreover, they found that by correcting a 
loss-of-function in PKC-β using Clustered Regularly-Interspaced Short Palindromic 
Repeats (CRISPR) they could reduce tumor growth in a xenograft model of a patient-
derived colon cancer cell line. This study suggests that PKC isoforms act as tumor 
suppressors rather than oncogenes, and that clinical studies are inconclusive as they 
are focusing on diminishing PKC, rather than attempting to restore PKC function in 
patients.  
Despite these conflicting results, PKC-β inhibitors have also shown positive results in 
breast cancer patients in preclinical and clinical studies. The potent PKC-β inhibitor, 
Enzastaurin, could inhibit tumor growth and angiogenesis in human tumor 
xenografts. Likewise, Phase II clinical trials involving Enzastaurin in patients with 
high-grade gliomas and lymphomas have shown promising results, and prove the 
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safety for this inhibitor in terms of effectiveness and toxicity (Sledge and Gokmen-
Polar, 2006). 
In this review we will focus mainly on the PKC-β isoform as this thesis explores the 
effect of the PKC-β inhibitor Enzastaurin on Paclitaxl-sensitivity in breast cancer 
cells.  
1.5.5. The role of PKC-β in cell cycle regulation 
 
The fact that PKCs are downstream of various growth factors led to the idea that they 
have an effect on mitotic signals. Indeed, PKCs can influence cell cycle, but 
depending on various cell internal and external factors, they can have positive or 
negative effects on cell cycle progression (Black, 2010). The effect of the PKCs is 
dependent on the timing and duration of PKC activation, the specific PKC isoform 
involved, the cellular context, cell type, and the signaling environment. PKCs can 
influence the activation of various cell cycle regulatory proteins, such as cyclins, 
cyclin-dependent kinases (CDKs), and CDK inhibitors, whereby p21Waf/Cip1 and cyclin 
D1 seem to be the key targets.  
The role of PKC-β in cell cycle is largely stimulatory. It has been shown to have 
effects on the G1 phase through phosophorylation and stimulation of CAK activity 
(Acevedo-Duncan et al., 2002), promotion of Rb phosphorylation (Suzuma et al., 
2002), and enhancement of cyclin D1 expression in breast cancer cells (Li and 
Weinstein, 2006). It is also critical for nuclear lamina disassembly during the G2/M 
transition by phosphorylating lamin B in K562 erythroleukemia cells (Thompson and 
Fields, 1996). Most importantly, PKC-β has been shown to regulate microtubule 
function. It was found that PKC can phosphorylate the microtubule-associated 
protein, tau, at Serine8 in peptide 369 (Correas et al., 1992). Tau proteins stabilize 
microtubules and promote tubulin assembly, however, both of these functions are 
reduced when it is phosphorylated by PKC at its tubulin binding domain. Further 
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phosphorylation by PKC on other Serine phosphorylation sites may even further 




















1.6 Aims and objectives of the study 
 
One of the major complications in the treatment of TNBC patients is the high rate of 
relapse after an initial positive response to a combination of different types of 
chemotherapeutic agents. Many patients suffer from residual disease and the relapse 
rate is high. A retrospective analysis of 269 TNBC patients found that the 5-year 
disease-free survival was only 68.2% with most patients suffering recurrent disease in 
the first 3 years following diagnosis (Ovcaricek et al., 2011). Once the patients 
present with metastatic or relapsed disease, the survival time rarely exceeds 1 year. 
The reason for this is that relapsed disease is often resistant to chemotherapy, and 
combined with the lack of effective targeted therapies, the treatment options are 
limited. 
Our aim was therefore to generate a model of Paclitaxel-resistance in TNBC which 
mimics the situation in a patient who develops chemo-resistant recurrent disease after 
chemotherapy treatment. Applying a top-down approach to our model we then sought 
to identify pathways which play a crucial role in resistance and are more highly 
activated in resistant compared to parental cell lines. At the same time we aimed to 
discover compounds that can revert resistance and sensitize resistant cell lines to 







































2.1. Cell culture and treatments 
 
MDA-MB231 cell line was obtained from American Type Culture Collection ATCC 
(Manassas, VA) and SUM159PT was obtained from Asterand Bioscience 
(Hertfordshire, UK). MDA-MB231 and its resistant derivatives were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®) supplemented with 10% 
fetal bovine serum (FBS) and 5000U/mL penicillin/streptomycin (Invitrogen). 
SUM159PT and its resistant derivatives were cultured in Ham’s F-12 Nutrient Mix 
medium with L-Glutamine (Gibco®) and supplemented with 5% FBS, 10mM HEPES 
(Gibco®), 5ng/ml Insulin, 1μg/ml hydrocortisone and 5000U/mL 
penicillin/streptomycin. All cell lines were maintained at 37°C with 5% CO2 in a 
humidified atmosphere. In addition, the resistant cell lines were maintained in 
different concentrations of Paclitaxel: 500nM, 1uM, 50nM and 75nM for SUM159PT 
500nM-TR and 1uM-TR, and MB231 50nM-TR and 75nM-TR, respectively. For all 
cell-based assays, the cells were seeded without Paclitaxel and treatment was started 
24 hours later.  
2.2. Cryopreservation of cell lines 
 
Cell lines were kept long-term in a liquid nitrogen tank (at -196°C) and short-term 
(~6 months) at -80°C. To recover cell lines, they were thawed at 37°C and neutralized 
with 8ml complete media. They were then spun down at 1000rpm for 3 mins and the 
cell pellet was resuspended in 10ml complete medium and seeded in a 75cm2 flask. 
Cells were grown and allowed to stabilize for 1 week before they were used for 
experiments. Cells were used for approximately 25 passages, after which they were 
discarded and new vials of frozen cells were recovered. To freeze down cells, they 
were trypsinized, neutralized with complete medium and spun down at 1000rpm for 3 
mins. Cells from one 150cm2 flask (80% confluency) were then resuspended in 5ml 
freezing medium (90% FBS and 10% DMSO) and 1ml aliquots were transferred into 
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cryovials. For the freezing process, cryovials were placed into a Mr. Frosty cylinder 
(NALGENE) which was filled with 99% isopropanol prior to transferring it into the -
80°C freezer. After one week, the cells were transferred to the liquid nitrogen tank.  
2.3. Generation of Paclitaxel-resistant cell lines 
 
Two TNBC cell lines were used to generate Paclitaxel-resistant derivatives, 
SUM159PT and MDA-MB231. Prior to treatment, the EC50 to Paclitaxel was 
measured for both cell lines. Cells were seeded in 6-well plates at a concentration of 
0.5x105 cells/ml, 2ml per well and the treatment was started the next day at half the 
concentration of the EC50. Once the surviving cells had recovered and started 
proliferating again, the cells were passaged into a new plate and the Paclitaxel 
concentration was doubled. This cycle continued until the final Paclitaxel 
concentrations were achieved for all four resistant cell lines (Figure 1A). For each of 
the two cell lines, 2 resistant derivatives were generated: SUM159PT 500nM-TR and 
1uM-TR, and MDA-MB231 50nM-TR and 75nM-TR, growing in 500nM, 1μM, 
50nM and 75nM Paclitaxel, respectively. The resistant cell lines were constantly 
maintained in medium supplemented with Paclitaxel. 
2.4. Transfection of small interfering RNA 
 
siRNA transfection of cell lines was conducted using Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s protocol. Target-specific siRNA and 
non-targeting control siRNA were purchased from Sigma Aldrich. Two target 
sequences were used to knock-down AURKB: 1. siAurB (Pre) is pre-designed by 
Sigma Aldrich (SASI_Hs01_00076963); 2.  siAurB is custom designed according to 
the sequence used by Ditchfield et al. (Ditchfield et al., 2003): 5’-
AACGCGGCACUUCACAAUUGA-3’. Non-targeting control used is MISSION® 
siRNA Universal Negative Control #1 (SIC001) (Sigma Aldrich). For siRNA 
transfection, 4μL siRNA (stock concentration 10μM) and 4μL RNAiMAX were 
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diluted in 100μL Opti-MEM medium (Invitrogen). After 5 minutes of incubation, 
both solutions were combined and incubated for another 20 minutes at room 
temperature. Before adding the transfection mixture onto the cells which were seeded 
in 6-well plates 18 hours earlier (1x105 cells/well), medium was changed to 800μL 
fresh complete medium. The end concentration of the siRNA used is 40nM. 24 hours 
later, the cells were then trypsinized and re-seeded for further down-stream assays. 
2.5. EC50 calculation 
 
To measure the resistance of cell lines to various chemotherapeutic drugs, the half 
maximal effective concentration (EC50) of the drugs was calculated in those cell lines. 
This value gives the concentration of a drug, which induces a response halfway 
between the baseline and the maximum. It is used to measure the potency of a drug 
and thereby resembles the sensitivity/resistance of cells to the drug. To measure the 
EC50 of various drugs in different cell lines, a cell viability assay was used (see Cell 
viability assay). The cells were treated 24 hours after seeding with 9 different drug 
concentrations and a control. As the cell lines had different sensitivity to the chemo-
drugs, different concentrations were used: 1) Paclitaxel and Vincristine: working 
concentrations of 10μM, 5μM, 1μM, 500nM, 100nM, 10nM, 1nM, 0.1nM, 0.01nM; 
2) Adriamycin: 50μM, 10μM, 5μM, 1μM, 100nM, 10nM, 1nM, 0.1nM, 0.01nM. Cell 
viability was measured after 4 days treatment and GraphPad Prism was used to plot a 
sigmoidal-dose response curve (three-parameter logistic equation) to measure the 
EC50 concentration of the chemo-drugs. 
2.6. Cell viability assay 
 
To measure the cell viability of cells in response to treatment, 1250 cells were seeded 
per well in a volume of 100μl in a white, opaque 96-well plate. After 24 hours, the 
media was changed to fresh media containing the drugs in the working concentration. 
Cell viability was measured every day for 5 days, or after 4 days of treatment, using 
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the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) according to the 
manufacturer’s instructions.  
2.7. Flow Assisted Cytometry Analysis (FACS) 
 
1x105 cells were seeded in 2ml complete medium per well in 6-well plates. 24 hours 
later, the drugs were added into the wells, and the cells were harvested 4 days after 
treatment. The cells were trypsinized, neutralized with complete medium and spun 
down at 1000rpm for 3 mins. The cell pellet was washed once with 1.5ml ice-cold 
phosphate-buffered saline (PBS) (Invitrogen) and then resuspended in 1ml ice-cold 
70% ethanol. The samples were kept at 4°C for at least one hour and maximum 7 
days. To stain the fixed cells, they were washed once with PBS and the cell pellet was 
treated with RNase for 5 mins at room temperature (RT). Then 400μl of a 50μg/ml 
Propidium Iodide (PI) solution was added to each sample, and they were incubated in 
the dark at RT for 30 mins. The stained cells were analyzed for their DNA content by 
FACS with FACSCalibur (Beckton Dickinson Instrument). The percentage of cell 
death was defined as the SubG1 population quantified using the CellQuest software 
(Beckton Dickinson).  
2.8. Phospho-Histone H3 (Ser28) assay 
 
The cells were treated for 24 hours after which they were washed with PBS and fixed 
in 1ml ice-cold PBS for at least one hour but not more than 7 days. They were then 
washed twice with PBS, blocked in 1ml blocking buffer (PBS, 0.1% Tween-20) for 
15 mins on ice, washed with 1ml staining buffer (PBS, 1% FBS) and transferred to a 
1.5ml Eppendorf tube. The cells were spun down at 2000rpm for 2 mins and the 
supernatant was vacuumed, leaving approximately 40μl with the cell pellet. The cells 
were incubated with 10μl anti-Phospho-Histone H3 (Ser28) antibody (Cell Signaling 
Technology, #9713) for 45 mins in the dark at room temperature. The cells were then 
washed once with PBS, incubated with 50μl RNase for 5 mins, followed by 400μl 
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Propidium Iodide (50μg/ml) for 30 mins in the dark. The samples were analyzed 
using FACS.  
2.9. Caspase 3 assay 
 
Caspase 3 is a marker for cells undergoing apoptosis and consists of a heterodimer of 
17 and 12kDa subunits derived from a 32kDa proenzyme. The FITC-conjugated anti-
active Caspase 3 antibody was used to detect cells with activated Caspase 3 by flow 
cytometry (BD Biosciences, #559341). The cells were seeded at a concentration of 
1x105 cells/well in 2ml/well of 6-well plates and subjected to different treatment 
groups 24 hours later. 24 hours after treatment, the cells were trypsinized and stained 
with the FITC-conjugated anti-active Caspase 3 antibody according to the 
manufacturer’s instructions. In short, the cells were washed with cold PBS once and 
fixed in Cytofix/Cytoperm solution for 20 mins. They were then washed twice with 
the Perm/Wash buffer and incubated with the FITC-conjugated anti-active Caspase 3 
antibody for 1 hour. Then they were washed with the Perm/Wash buffer once and 
analyzed by flow cytometry using the FACSCalibur. The amount of cells with active 
Caspase 3 was determined using the CellQuest software. 
2.10. Anchorage-independent Methylcellulose assay 
 
The wells of an opaque 96-well plate with clear bottoms were coated with BactoTM 
Agar before being used for this assay. To do so, the agar was dissolved in PBS to a 
concentration of 3% and boiled until it was dissolved completely. It was then mixed 
with complete medium to a final concentration of 0.6% and 80μl were used to coat 
the bottom of each well. The plates were kept in the incubator (37°C, 5% CO2) for at 
least 45 mins before use. The Methylcellulose powder (4,000 cP viscosity, 2% in 
H2O; Sigma-Aldrich, St. Louis, MO) was autoclaved and dissolved in autoclaved 
H2O to make a 2% stock solution. The cells were resuspended in fresh medium and 
the cell concentration was measured. Consequently, the cells were diluted to a 
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concentration of 2x104cells/ml in 30ml complete media, and 10ml of 2% 
Methylcellulose solution was added. The final cell concentration attained was 
1.5x104cells/ml in complete media with 0.5% Methylcellulose. 1ml aliquots were 
made to which the drugs were added and 100μl were seeded per well. Subsequently, 
the cells were allowed to grow for 13 days in the incubator before they were stained 
with 80μl of a 40μg/ml p-Iodonitrotetrazolium Violet (INT) solution and the colonies 
were counted and analyzed using the GelCountTM automatic plate scanner (Oxford 
OPTRONIX) and the GelCount Version 0.025.1 software (Oxford OPTRONIX). 
Plates were scanned at 1200 dpi. 
2.11. Tumorsphere assay 
 
To measure the number of tumor-initiating cells, a tumorsphere assay was performed. 
The tumorsphere medium used to grow breast cancer tumorspheres (mammospheres) 
consists of 90ml MammoCultTM Basal Medium (Human) (STEMCELLTM 
Technologies, Vancouver, CA), supplemented with 10ml MammoCultTM 
Proliferation Supplements (Human) (STEMCELLTM Technologies), 200μl heparin 
solution (stock 0.2%), and 200μl hydrocortisone (stock 250μg/ml). Cells were 
trypsinized, neutralized with complete medium and spun down at 1000rpm for 3 
mins. The cell pellet was washed once with 5ml PBS, resuspended in 3ml 
tumorsphere media, and the cell count was determined. 5,000 cells were seeded in 
one well of a low-attachment 96-well plate in a volume of 2ml and placed in the 
incubator. After 24 hours, the drugs were added into the wells without changing the 
medium. Three days later, the wells were topped-up with 1ml of fresh tumorsphere 
medium, and after 7 days 300μl of a 40μg/ml INT solution were added per well and 
incubated over night to stain the tumorspheres. The INT end concentration is 4μg/ml. 
The number of tumorspheres was measured the next day using the GelCountTM 
automatic plate scanner and the GelCount software. Plates were scanned at 1200 dpi 
and the colony detection algorithm was optimized for each cell line individually.  
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2.12. 3D Matrigel anchorage-independent growth assay 
 
An 8-well chamber slide (#384118, BD Biosciences) was pre-coated with 45μl of 
7.6mg/ml growth factor-reduced matrigel (#356231, BD Biosciences) for 30 mins at 
37°C. 5x103cells in a volume of 400μl in complete media with 150μg/ml matrigel 
containing the different concentrations of the drugs were seeded into each well. The 
cells were placed in the incubator and media was replaced with fresh media after 4 
days. Phase contrast images were taken of the cells at different time points.  
2.13. RNA extraction 
 
Cell pellets were collected by trypsinizing monolayer cells, and the cell pellet was 
washed once with ice-cold PBS. The cells were resuspended in 700μl Qiazol 
(Invitrogen) to lyse the cells, after which 200μl chloroform was added and the 
mixture was centrifuged at 13,000rpm for 15 mins at 4°C to separate RNA, DNA and 
other cellular components. After centrifugation, the top clear layer was transferred 
into a fresh 1.5ml eppendorf tube, followed by the addition of 540μl 100% ethanol. 
The miRNeasy mini kit (Qiagen) was used to purify the RNA. In short, the samples 
were transferred to the column and the RNA was allowed to bind to the membrane 
via centrifugation. The columns were washed once with 700μl RW1 buffer, and twice 
with 500μl RPE buffer. Subsequently, the RNA was eluted from the column with 
50μl RNAse-free water. The concentration of the RNA was determined using a 
NanoDrop ND-1000.  
2.14. cDNA conversion and quantitative RealTime-PCR (RT-PCR) 
 
To transcribe RNA into single-stranded complementary DNA (cDNA), a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used. Briefly, 
750ng of RNA were diluted in 25μl RNAse-free water. Then a master mix was 
prepared with 5μl RT buffer, 5μl random primers, 2μl dNTP mix, 2.5μl 
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MultiScribeTM reverse transcriptase, and 10.5μl RNAse-free water, which was added 
to the previously prepared RNA. A PCR was then performed in a thermo cycler at 
25°C for 10 mins, followed by 37°C for 2 hours. To perform quantitative RealTime-
PCR, 0.44μl of the cDNA (15ng/μl) was added to 3.96μl RNAse-free water. 
Concurrently, 0.4μl gene-specific primer mix (10μM) was added to 5μl of 2X master 
mix from KAPA SYBR® FAST qPCR Kit (Kapa Biosystems). The two reactions 
were then mixed together and subjected to quantitative RealTime-PCR. The reaction 
mix was amplified and quantified with PRISM 7900 Sequence Detection System 
(Applied Biosystems). 18S or Actin were used as internal controls. All the reactions 
were analyzed using Applied Biosystems PRISM 7500 Fast Real-Time PCR system 
in 96-well plate format.  
 
Table 2.13 Primers used for quantitative RealTime-PCR of target genes 
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2.15. Microarray gene expression profiling 
 
To control the quality of the mRNA used and to detect mRNA degradation, Agarose 
gel electrophoresis was performed on a 1% Agarose gel. The microarray 
hybridization was performed using the Illumina Gene Expression Sentrix BeadChip 
HumanRef-8_V2 (San Diego, CA). In short, 500ng of RNA was used to perform 
cDNA conversion and further processed into double-stranded cDNA. The purified 
cDNA was used to generate biotinylated cRNA, which was likewise purified before 
further processing. The biotinylated cRNA was hybridized onto the BeadChip, 
washed, and stained with streptavidin-Cy3. The BeadChip was scanned using the 
Illumina BeadArray Reader and the images were stored with indicated barcodes. 
Illumina GenomeStudioTM was used to analyse the scanned images and the output 
was used for further analysis with GeneSpringGXTM (Agilent Technology). The data 
were analyzed by selecting Illumina single color as the experimental type and quartile 
normalization was performed for the readings. Fold changes in gene expression of the 
resistant cells lines were analyzed by pair-wise comparisons to the respective parental 
cell lines.  
2.16. Protein extraction  
 
For total protein extraction, the cells were trypsinized, neutralized with complete 
medium and spun down at 1200rpm for 3 mins and washed once with 1.5ml ice-cold 
PBS. The volume of the cell pellet was estimated and resuspended in 5x the volume 
of radioimmunoprecipitation assay (RIPA) lysis buffer (50nM Tris-HCl pH7.4, 1mM 
EDTA, 150mM NaCl, 1% Igepal CA630, 0.5% sodium deoxycholate, 1mM 
Na3VO4, 20mM NaF, 1mM PMSF, and complete protease inhibitor (Roche)). The 
samples were kept on ice for 30 mins and vortexed every 5 mins for 10 seconds, and 
then sonicated  3x 5 seconds at 20% maximum force, after which they were spun 
down at 13,200rpm for 15 mins at 4°C. The supernatant containing the protein was 
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transferred into a fresh eppendorf tube and the concentration was estimated with the 
DC Protein Assay (Bio-Rad) using BSA to generate a standard curve, and measured 
using the Tecan XflourTM software.  
2.17. Western blotting 
 
A 10% or 12% SDS-PAGE gel was used to separate protein samples (20-30ug), 
which were then transferred onto a PVDF membrane (Milipore) at 23V for 70 mins 
using the Trans-Blot SD Semi-Dry transfer cell (Bio-Rad). The membranes 
containing the protein were blocked with 5% non-fat milk (Bio-Rad) or 5% bovine 
serum albumin (BSA) for 2 hours, or overnight. The primary antibodies were diluted 
to their recommended working concentrations using the blocking buffer and 
incubated on the membranes overnight, or for 2 hours RT, according to the 
manufacturer’s instructions. The membranes were washed 3 times for 5 mins using 
the washing buffer and incubated with the HRP-conjugated secondary antibody 
diluted in blocking buffer for 1 hour at RT. The membranes were incubated with the 
chemiluminescent ECL Substrate Kit (GE Healthcare) for 5 mins, and the signal was 
subsequently detected using the ChemiDocTM Imaging System (BIO-RAD). The blots 
were probed with primary antibodies against PKC-β (GTX113252) purchased from 
GeneTex; phospho-PKC-βI (Thr641) (sc-101776), PKC (sc-80) and MCL-1 (sc-819) 
purchased from Santa Cruz Biotechnology Inc.; Aurora B/AIM1 (#3094S), phospho-
Aurora A/B/C (T288/232/398) (#2914S), phospho-C-Raf (Ser289/296/301) (#9431P), 
phospho-GSK3β (Ser9) (#5558S) and cleaved PARP (#9541S) purchased from Cell 






2.18. H-score calculation 
 
H-score was used as a semi-quantitative analysis to describe the extent of 
immunohistological staining of patient tumor samples. The formula used is the 
following: 
 
Samples used to calculate H-score are derived from The Human Protein Atlas 
(www.proteinatlas.org). Patient samples made available from this database were 
stained with 2 different anti-PKC-β antibodies and grouped into low, medium and 
high intensity staining. According to this grouping, the H-score was calculated for 
normal breast tissue and breast cancer samples.  
2.19. Statistical analysis 
 
Statistical analyses of XY and bar graphs were performed using the GraphPad Prism 
software. Experimental readings were performed in duplicates, triplicates or 6 
replicates and a Student’s T-test was used to generate p-values for measuring 
significance between measurements. All statistical tests and graphs are generated with 



































3.1. Generation and characterization of Paclitaxel-resistant TNBC cell 
lines 
 
To study mechanisms of acquired chemo-resistance in Triple Negative Breast Cancer 
(TNBC) cell lines and, subsequently, find ways to revert resistance we generated 
chemo-resistant cell lines. We used Paclitaxel-resistance as a model as it is used in 
first line treatment for patients harboring triple negative breast tumors. To generate 
this model we used the two TNBC cell lines, SUM159PT and MDA-MB-231 
(hereafter named MB231). The cell lines were seeded in a 2D culture and treated with 
a Paclitaxel starting concentration of ½ of the EC50 concentration which leads to a 
reduction of cell viability and apoptosis in approximately 30% of the cells. As soon as 
the remaining cells had stabilized and started proliferating again, the Paclitaxel 
concentration was doubled (Figure 3.1.1 (A)). After approximately 5 months, we had 
generated two resistant derivatives for each of the two TNBC cell lines, stably 
growing in different Paclitaxel concentrations. For SUM159PT, the resistant cell lines 
grow in 500nM and 1μM Paclitaxel, and are termed 500nM-TR and 1μM-TR. The 
MB231 resistant cell lines grow in 50nM and 75nM Paclitaxel, and are therefore 
called 50nM-TR and 75nM-TR, respectively. The parental MB231 cell lines show a 
lower intrinsic resistance to Paclitaxel, therefore the resistant cell lines cannot be 
stably grown in higher concentrations. To measure resistance, we calculated the EC50 
of Paclitaxel in these cell lines using a cell viability assay. The EC50 is the 
concentration of a drug which gives a response halfway between the baseline and the 
maximum. As seen in Figure 3.1.1 (B) and (C), the resistant cell lines show ~1000-
fold and 300-fold higher EC50 value compared to their chemo-sensitive counterparts 









Figure 3.1.1 Generation of Paclitaxel-resistant 
TNBC cell lines 
A. Paclitaxel-sensitive parental SUM159PT 
and MB231 cell lines were treated with 
½ of the Paclitaxel EC50. After initial 
reduction in cell viability and cell death, 
the remaining cells were further cultured 
and the Paclitaxel concentration was 
doubled. This cycle was repeated until 2 
resistant derivatives were derived from 
each cell line: SUM159PT 500nM-TR 
and 1μM-TR; and MB231 50nM-TR and 
75nM-TR  
B. Paclitaxel EC50 for both parental and the 
resistant cell lines was measured using 
cell viability assay. The cells were 
treated 24 hours after seeding and cell 
viability was measured after 4 days 
treatment (n=6). The EC50 was calculated 
using Sigmoidal dose-response and 
plotting the non-linear regression curve 
fit (Error bars show ±SD, n=6) 
C. Bar graph depicting the increase in 
Paclitaxel EC50 in the resistant compared 
to the parental cell lines, as measured 






As we know, chemo-resistance has been linked to cancer stem cells (CSCs), as these 
are believed to confer resistance through mechanisms such as up-regulation of anti-
apoptotic proteins such as Bcl-2, and high expression of ABC transporters for 
effective efflux pumping. Therefore, we examined the population of CSCs in the 
resistant cell lines which can be identified by the expression of specific cell surface 
markers. Breast CSCs are characterized by a high expression of CD44 and a low 
expression of CD24. FACS analysis revealed a 3-fold increase in the CSC population 
in the SUM159PT resistant cell lines, and a 3- and 5-fold higher amount in the 
MB231 50nM-TR and 75nM-TR cell lines, respectively (Figure 3.1.2 (A) and (B)). 
These results are in concordance with other studies showing an increase in the CSC 
population in chemo-resistant ovarian and colorectal cancer cell lines (Cole et al., 
2014, Dallas et al., 2009). We performed a tumorsphere assay in order to validate the 
increase in CSCs in SUM159PT parental and resistant cell lines (Figure 3.1.2 (C)). 
Surprisingly, the tumorspheres generated by the SUM159PT resistant cell lines show 
a different morphology compared to the parental cell lines. While the parental cell 
lines build round distinct spheres, the spheres generated by the resistant cell lines 
seem to be aggregating. It can be ruled out that these are merely simple cell 
aggregates as they cannot be dissociated easily by pipetting and need to be 
trypsinized to generate single cells, a characteristic of spheres with intact cell-cell 
interactions (Manuel Iglesias et al., 2013). In addition, the high expression of the cell 
surface marker CD44 can make the cells more “sticky”, so the spheres are able to 



















When we checked for the expression of the breast CSCs markers, CD44 and CD24, 
we found that the expression of CD24 was reduced in the parental SUM159PT cell 
line compared to the resistant cell lines, whereas there was an increased expression of 
CD44 in the resistant cell lines. These results validate our FACS analysis, which 
identified an increase in the CD44+/CD24- CSCs population in the resistant 










Figure 3.1.2 Increase in the cancer stem cell population in Paclitaxel-resistant cell lines 
A. FACS analysis of SUM159PT and MB231 parental and resistant cell lines. The cells 
were stained with APC- and FITC-conjugated CD24 and CD44 antibodies, 
respectively. 
B. Bar graph depicting the percentage of CD24-/CD44+ population in parental and 
resistant cell lines as determined by FACS analysis (A). 
C. Images of tumorspheres of SUM159PT parental, 500nM-TR and 1μM-TR cell lines 
after 7 days growth in anchorage-independent conditions. 
D. RealTime-PCR was performed on SUM159PT parental and resistant cell lines to 
determine mRNA expression of CD44 and CD24. mRNA expression values were 




3.2. Gene expression profiling of SUM159PT Paclitaxel-resistant cell lines 
 
To gain insights into the differential regulation of genes and pathways in the resistant 
derivatives of SUM159PT compared to the parental cells, we performed microarray 
analysis. After analyzing the microarray data with GeneSpringGXTM, we extracted 
the list of genes significantly up-regulated in the 500nM-TR and 1uM-TR compared 
to the parental cell line (fold change > 2; FDR<0.05) and analyzed them with 
Ingenuity Pathway Analysis® (IPA). We examined the functions and pathways that 
these genes are involved in and plotted the predicted Activation Z-score for each 
pathway. This score represents the bias in gene regulation and predicts whether this 
pathway is activated (Activation Z-score  > 2) or inhibited (Activation Z-score < -2). 
 We found that genes up-regulated in both cell lines lead to an increased activation of 
pathways and functions such as Cell Death and Survival, Cellular Movement, 
Cellular Assembly and Organization, and Cellular Development, Growth and 
Proliferation, among others (Figure 3.2.1). In contrast, increased activation of these 
genes leads to an inhibition of apoptotic and cell death pathways. These findings are 
not surprising as the resistant cell lines are maintained in Paclitaxel and are under 
constant survival pressure, although they have acquired resistance. This means that 
cell survival and proliferative pathways are up-regulated, while apoptotic pathways 
are down-regulated. Moreover, resistant cell lines show an increase in microtubule 
dynamics, a consequence of the mechanism of action of Paclitaxel, which stabilizes 
microtubules, in order to maintain an intact cell cycle and chromosome segregation. 
This comes hand in hand with an activation of cell cycle progression pathways, and 








3.2.1. The NF-κB network 
 
We then wanted to determine the gene networks which are more highly activated in 
the resistant cell lines compared to the parental cell line. IPA analysis lets us 
determine these networks and ranks them according to a score calculated by their 
algorithm. This score is calculated based on the p-value which takes into account the 
number of Focus Genes in a certain network. The p-value is calculated based on the 
probability of finding f or more Focus Genes in a set of n genes randomly selected 
from the Global Molecular Network and the size of the network to approximate its 
relevancy to the list of Focus Genes. Fisher’s exact test is used to calculate the p-
Figure 3.2.1 Changes in functions and pathways in Paclitaxel-resistant TNBC cell lines 
Microarray analysis was used to determine gene expression changes in the SUM159PT 
resistant compared to the parental cell lines. After quantile normalization, significantly over-
expressed genes (FDR<0.05, fold change>2) common in both resistant compared to parental 
cell lines (581 genes) were analyzed using Ingenuity Pathway Analysis®. The figure shows 
significantly altered pathways and functions according to the Activation z-score, which is 
dependent on the number of genes whose expression is significantly up-regulated in the gene 
sets for each specific function/pathway. 
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value which in turn is used to determine the p-score. This score is defined as:  
p-score= -log10(p-value). The top 5 networks with the highest scores when comparing 
gene expression values in the SUM159PT resistant compared to the parental cell lines 
are shown in Figure 3.2.2 (A). We zoomed into the highest ranked network and found 
that most of the genes involved belong to the NF-κB complex (Figure 3.2.2 (B)). We 
extracted the normalized gene expression values from the GeneSpring analysis of the 
genes from Network 1 which are NF-κB-related genes and validated them using 
RealTime-PCR (Figure 3.2.2 (C)). We found that, indeed, most of the genes are more 
highly expressed in the resistant compared to the parental cell lines, but expression 

















Figure 3.2.2 The NF-κB network 
in Paclitaxel-resistant cell lines 
A. IPA was used to determine 
enriched networks in 
SUM159PT 500nM-TR 
and 1μM-TR compared to 
the parental cell lines. 
Genes selected for the 
analysis were commonly 
up-regulated in both 
resistant cell lines and had 
a fold change cut-off=2 and 
FDR<0.05.  
B. The top network with the 
highest score has the NF-
κB complex at the centre. 
C. Gene expression values of 
genes which play a role in 
NF-κB signaling and are 
found in the top network. 
Gene expression values 
from microarray analysis 
shown are after quantile 
normalization and relative 
to the parental cell line 
(fold change>2, 
FDR<0.05). RealTime-
PCR analysis is normalized 
to gene expression values 
of SUM159PT parental 
cells. 18S was used to 
normalize mRNA 
expression values (Error 






It has been shown that the NF-κB pathway plays an important role in chemo-
resistance and inhibition of this pathway (using disulfiram and copper) sensitizes 
breast CSCs to Paclitaxel (Yip et al., 2011). To verify its role in our model of 
Paclitaxel-resistance in TNBC cell lines, we used various NF-κB inhibitors to test 
whether this pathway is more important for cell survival in the SUM159PT 500nM-
TR and 1μM-TR resistant cell lines compared to the parental cell line. We treated the 
cells for 4 days with 3 IKK inhibitors: 1. BAY 11-7082, an inhibitor of the IκB kinase 
(IKK) α subunit, IKKα, and of phosphorylation of cytokine-inducible IκBα 
(IC50=10μM); 2. PHA-408, a potent inhibitor of IKKβ (IC50=40nM); 3. PS-1145, a 
selective IKK inhibitor (IC50=100nM). The IKK kinase complex is made of the two 
kinases IKKα and IKKβ, where IKKα plays a role in the non-canonical NF-κB 
pathway and IKKβ in the canonical NF-κB pathway. As a negative control, to 
determine whether the effect of treatment is specific to the NF-κB inhibitors, we 
included a MEK inhibitor (PD0325901, IC50=0.33nM), and a PDK1 inhibitor 
(BX795, IC50=6nM). We found that the resistant cell lines were only slightly more 
sensitive to the NF-κB inhibitors compared to the parental cell line at high 
concentrations, although the parental cell line also responded to the inhibitors in a 
dose-dependent manner (Figure 3.2.3). The two inhibitors used as negative controls, 
MEK and PDK1 Inhibitors, showed a dose-dependent effect in the resistant and 
parental cell lines, although the resistant cell lines are more resistant compared to the 
parental cell line.  
These results don’t fit our hypothesis to identify activation of pathways specific to 
Paclitaxel-resistant cell lines. This could possibly be because the NF-κB pathway is 
important in TNBC, even without Paclitaxel-resistance, which is why various NF-κB 
inhibitors are only slightly effective in the resistant cell lines. We therefore decided to 
use a different approach to find pathways that play a role in Paclitaxel-resistance and 









Figure 3.2.3 SUM159PT Paclitaxel-resistant cells are equally sensitive to NF-κB inhibitors 
as compared to the parental cell line  
SUM159PT parental and 500nM-TR and 1μM-TR resistant cell lines were treated for 4 days 
with different concentrations for all inhibitors, after which cell viability was measured. All 
measurements are normalized to the DMSO control and the percentage is plotted. (Error bars 
show ±SD, n=3). 
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3.3. Kinase inhibitor screen to identify Paclitaxel-sensitizing compounds 
 
To identify compounds that can re-sensitize resistant TNBC cells to Paclitaxel, we 
performed a kinase inhibitor screen using 180 small molecule inhibitors targeting 
different kinases. This screen was used to detect synthetic lethal drug combinations 
with Paclitaxel, specific for the resistant cell lines.  
The cells were seeded in 96 well plates, treated 24 hours later and after 4 days 
treatment, cell viability was measured. The cells were treated either with the inhibitor 
alone, or in combination with Paclitaxel (Figure 3.3.1 (A)). We then calculated the Z-
score for each treatment group for each resistant cell line separately. Z-score 
calculations take into account the mean of a population (in this case the mean of all 
the cell viability measurements for each treatment group (inhibitor vs. inhibitor + 
Paclitaxel) for one cell line, and assigns each single measurement a score, depending 
on whether it is above or below the population mean. Scores > 0 mean that the cell 
viability is higher, whereas scores < 0 mean that cell viability is lower than the 
population mean. When Z-scores of the inhibitor single treatment vs. inhibitor + 
Paclitaxel treatment are plotted on a scatter plot (Figure 3.3.1 (B)), distinct 
populations can be identified. The inhibitors most interesting to us are the ones 
clustering in the II. Quadrant. These inhibitors show no effect on cell viability as 
single treatment but significantly reduced cell viability in the combination treatment. 
Inhibitors in the III. Quadrant also have an effect on the resistant cell lines as single 
treatment and are, therefore, not interesting to us as they are not targeting pathways 
specific to Paclitaxel-resistance. Inhibitors clustering in the I. Quadrant have no effect 
as single treatment or in combination with Paclitaxel and we also eliminated these. 
Many of the inhibitors in the II. Quadrant are PKC and PKC-β inhibitors, suggesting 











Figure 3.3.1 Kinase inhibitor screen identifies PKC-β inhibitors to be able to re-sensitize 
resistant cells 
A. Schema for performing the kinase inhibitor screen. The cells were seeded in 96-well 
plates and treated with 180 small molecule inhibitors targeting different kinases 24 
hours later. All the inhibitors were used at 5μM unless otherwise stated (Figure 3.3.2). 
One set was treated with the inhibitor alone, whereas another set was treated with the 
inhibitor in combination with Paclitaxel. Cell viability was measured after 4 days of 
treatment. Cell viability measurements were normalized to the DMSO control. 
B. After normalization, the Z-score was calculated for each inhibitor by determining the 
whole population mean for each cell line separately. The Z-score of single treatment 
was then plotted against the Z-score for combination treatment on a scatter plot. The 
inhibitors in the II. Quadrant are those with no effect as single treatment, but reduce 






To calculate whether the difference of single treatment vs. combination treatment was 
significant for each compound, we used a Student’s t-test to calculate p-values. We 
assumed that the cell viability measurements of the 4 resistant cell lines (SUM159PT 
500nM-TR and 1uM-TR, MB231 50nM-TR and 75nM-TR) are replicates in the two 
different treatment groups: inhibitor alone, and inhibitor + Paclitaxel. After 
calculating the p-value between the two treatment groups, and thereby identifying 
those inhibitors that have no effect when given as a single treatment but lead to 
reduced cell viability in combination with Paclitaxel, we ranked the inhibitors 
accordingly (Figure 3.3.2). As shown, some of the top hits included inhibitors 
targeting proteins which have been known to play a role in chemo-resistance, such as 
p38 in colorectal cancer (Grossi et al., 2014), the hedgehog pathway (Hh) in breast 
cancer and prostate cancer (Chai et al., 2013, Singh et al., 2012), EGFR in ovarian 
cancer cell lines (Servidei et al., 2008), the MEK5/ERK5 pathway, whose over-
expression was found to be associated with poor survival in breast cancer patients 
treated with chemotherapy (Miranda et al., 2015), and BTK which, when inhibited, 
can sensitize leukemic cells to chemotherapeutic drugs (Uckun et al., 2002).  
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Figure 3.3.2 Top hits of the kinase inhibitor screen 
The inhibitors were ranked according to the p-value calculating the significant difference in cell 
viability of inhibitor alone vs. combination treatment in the resistant cell lines. The cell 
viability measurements in the 4 resistant cell lines (SUM159PT 500nM-TR and 1μM-TR, and 
MB231 50nM-TR and 75nM-TR) for each treatment group were taken as replicates. Using this 
method the inhibitors were ranked according to how significantly they could reduce cell 
viability in combination with Paclitaxel, while having minimal effect as single agent. Cell 
viability measurements are color-coded with red depicting low, and green depicting high 
values. All inhibitors were used at 5μM unless stated otherwise. 
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3.4. Validation of top hits from the kinase inhibitor screen 
 
For further validation, we decided to focus on novel targets in chemo-resistance such 
as Kit/PDGFR, TNKS1/2, PKC-β, and FLT3, in addition to some of the previously 
published targets (p38 MAPK, Hh, BTK, PKA), which serve to validate our own 
screen, but also whose role specifically in breast cancer chemo-resistance is not clear. 
We first validated 9 inhibitors (highlighted in yellow) which target the 
aforementioned kinases with a cell viability assay at 2 different concentrations each 
(1μM and 5μM). As shown in Figure 3.4.1 (A) and (B), all the inhibitors lead to a 
reduction in cell viability in all the 4 resistant cell lines when used in combination 
with Paclitaxel, but have no effect as a single agent. In addition, they also have no 
effect in SUM159PT and MB231 parental cell lines. Cell viability is normalized to 
Day 0, which means that if the bar drops below CTG Signal=0, it is suggestive of 
apoptosis. In general, the SUM159PT resistant cells are more sensitive to the 
combination treatment, with more inhibitors leading to apoptosis, compared to the 









The only inhibitors which were able to reduce cell viability below 0 in combination 
with Paclitaxel in all the 4 resistant cell lines are the PKC-β inhibitors (LY333531 
and Enzastaurin), as well as the PKA inhibitor (H-89) (except in MB231 50nM-TR). 
Since the PKA inhibitor H-89 was also one of the top hits of the kinase screen with a 
significant p-value calculation, and PKA has been previously reported to play a role 
in chemo-resistance in breast cancer cells through regulation of the expression of the 
Figure 3.4.1 Validation of the top 9 hits identified by the kinase screen 
Validation of the 9 top hits in SUM159PT (A) and MB231 (B) parental and both resistant cell 
lines. The cells were treated with inhibitor alone (at 1μM and 5μM each) or in combination 
with Paclitaxel and cell viability was measured on Day 0 and Day 4. Day 4 measurements were 
normalized to Day 0 and values were plotted on the bar graph. All the inhibitors had no or 
minimal effect as single agent in the parental or resistant cell lines but could successfully 
sensitize resistant cells to Paclitaxel when compared to the Paclitaxel treatment alone. (Error 





MDR1 protein, we also used this inhibitor for the following validation assay (Cvijic 
and Chin, 1997).  
 We performed a Methylcellulose assay which measures colony formation in 
anchorage-independent conditions. We found that both PKC-β inhibitors (LY333531 
and Enzastaurin) and the PKA inhibitor (H-89) given at 1μM and 5μM each, led to a 
significant decrease in the number of colonies in combination with Paclitaxel, but not 
as single treatment (Figure 3.4.2 (A) and (B)). Additionally, the effect was slightly 
stronger with the PKC-β inhibitors compared to the PKA inhibitor at low 
concentrations, as seen for the SUM159PT resistant cells. Interestingly, the resistant 
cell lines showed no change or a slight increase in colony formation in the Paclitaxel 
compared to the DMSO treatment groups, suggesting that the resistant cells, to some 











Figure 3.4.2 PKC-β and PKA inhibitors can inhibit colony formation of Paclitaxel-
resistant cell lines in the presence of Paclitaxel 
Validation of the PKC-β (LY333531, Enzastaurin) and PKA (H-89) inhibitors in SUM159PT 
(A) and MB231 (B) in an anchorage-independent Methylcellulose assay. The cells were seeded 
in a Methylcellulose assay and treated for 13 days before the colonies were stained with INT 
o/n. The plates were then scanned using a GelCount and colonies/well were counted. The 
inhibitors could significantly reduce colony formation in the resistant cell lines in combination 





For subsequent experiments, a Paclitaxel treatment control was added for all the 
parental cell lines where they were treated with a very low dose of Paclitaxel. This 
dose was derived from the cell survival of the resistant cell lines in their maintenance 
doses of Paclitaxel. For SUM159PT, the 500nM-TR cell line is cultured in 500nM 
Taxol, and according to the Sigmoidal curve formula when calculating the EC50, 
98.9% of the cells survive. We then calculated how much Paclitaxel is needed for the 
parental cells, so that 98.9% survive. For SUM159PT parental cells, 98.9% cell 
survival is achieved with 0.73nM Paclitaxel. For MB231 parental cells the Paclitaxel 
















3.5. The PKC-β and PKA inhibitors sensitize resistant cells and induce 
apoptosis in the presence of Paclitaxel 
 
To test whether the reduction in cell viability after combination treatment is really 
due to an induction of cell death, we performed 2 different apoptotic assays: Caspase 
3 and Propidium Iodide (PI) staining. Both assays are flow cytometry-based, where 
the former detects cells with activated Caspase 3, and the latter detects the apoptotic 
cell population based on DNA fragmentation. For these assays we used the PKC-β 
inhibitor Enzastaurin and the PKA inhibitor H-89. We first performed a Caspase 3 
assay and found that single treatment with either of the inhibitors had little to no 
effect on the activation of Caspase 3 in any of the resistant cell lines (Figure 3.5.1). 
However, in combination with Paclitaxel we observed a significant increase in 
Caspase 3+ cells, whereby the combination with Enzastaurin yielded the greatest 
amount of apoptotic cells in all 4 resistant cell lines. The combination treatment with 
the PKA inhibitor and Paclitaxel only resulted in a mild increase in Caspase 3+ cells. 
As expected, Paclitaxel treatment alone could not increase the amount of Caspase 3+ 
cells in the resistant cell lines. Moreover, the parental cell lines showed a slight 
increase in Caspase 3+ cells after single treatment with Enzastaurin alone, but there 











We then performed PI staining to validate these results in the resistant cell lines. We 
treated the cells for 4 days with either the inhibitors alone or in combination with 
Paclitaxel. The cells were then fixed and stained with PI which intercalates into the 
Figure 3.5.1 PKC-β and PKA inhibitors induce Caspase 3 activation in the presence of 
Paclitaxel 
Measurement of Caspase 3+ cells after treatment with PKC-β and PKA inhibitors at different 
concentrations with and without Paclitaxel in SUM159PT (A) and MB231 (B) parental and 
resistant cell lines. The Paclitaxel concentration used for SUM159PT and MB23 parental cells 
is 0.73nM and 0.46nM, respectively, whereas for the resistant cells, the maintenance 
concentration was used. The cells were treated for 4 days, after which they were fixed with 
70% ethanol for 1 day and then stained with a FITC-conjugated anti-Caspase 3 antibody. FACS 




DNA, thereby allowing us to measure the DNA content of the cells. A normal 2N 
DNA content means that the cells are in the G1 phase, a DNA content of 4N means 
that the cells are in the G2/M phase, and a DNA content less than 2N suggests that 
the cells have undergone DNA fragmentation due to apoptosis. This is called the 
SubG1 population which can be measured using this assay and represents the 
population of apoptotic cells. As can be seen in Figure 3.5.2, single inhibitor 
treatment did not lead to apoptosis, whereas the combination with Paclitaxel lead to a 
significant increase in the amount of apoptotic cells in the resistant cell lines in a 
dose-dependent manner. Interestingly, the percentage of cells undergoing apoptosis 
was greater when they were treated with the PKC-β inhibitor Enzastaurin as 











We therefore decided to focus on PKC-β as a target for chemo-resistance in triple 
negative breast cancer cells. For one, in the top 40 hits of the kinase inhibitor screen, 
3 target hits were PKC-β inhibitors (LY333531, Enzastaurin and LY317615), and one 
was a pan-PKC inhibitor (Sotrastaurin) (Figure 3.4). This is strongly indicative of the 
importance for the role of PKC-β in chemo-resistance. Secondly, it has a significant 
effect in reducing cell viability and anchorage-independent growth in resistant cells, 
and induces high levels of apoptosis in combination with Paclitaxel. And thirdly, 
PKC-β inhibitors are the most advanced in clinical trials out of all the validated hits, 
and have undergone successful Phase III clinical trials for complications of diabetes 
(Danis and Sheetz, 2009), as well as various pre-clinical and clinical trials for 
treatment of patients with different hematological and non-hematological cancers, 
such diffuse large B-cell lymphoma (DLBCL) (Robertson et al., 2007), non-small cell 
lung cancer (Oh et al., 2008), metastatic colorectal cancer (Glimelius et al., 2010), 
and recurrent high-grade gliomas (Kreisl et al., 2010). Although the responses have 
been mixed and negative so far, Phase II studies were conducted which used 
Enzastaurin in combination with Paclitaxel and Carboplatin as first-line treatment for 
ovarian cancer to increase progression-free survival (Vergote et al., 2013). 
Enzastaurin is an oral drug with high safety in patients, also in combination with 
chemotherapeutic drugs. This PKC-β-specific inhibitor was advanced for clinical 
development due to its anti-angiogenic activity in human tumor xenografts , where it 
leads to decreased VEGF expression and microvessel density (Keyes et al., 2004).  
Figure 3.5.2 PKC-β and PKA inhibitors increase SubG1 fraction in Paclitaxel-resistant cell 
lines in the presence of Paclitaxel  
Measurement of SubG1 fraction upon treatment with PKC-β and PKA inhibitors at different 
concentrations with and without Paclitaxel in SUM159PT (A) and MB231 (B) resistant cell 
lines.  The cells were treated for 4 days with Enzastaurin and H-89 alone or in combination with 
Paclitaxel, and subsequently fixed with 70% ethanol for 1 day. They were then stained with 
Propidium Iodide for 30 mins before they were analyzed by FACS. Both inhibitors were able to 
increase SubG1 fraction in the resistant cell lines upon Paclitaxel treatment, whereas Paclitaxel 
alone is not sufficient to induce cell death. (n=1). 
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3.6. The PKC-β inhibitor Enzastaurin sensitizes chemo-resistant cells to 
Paclitaxel in anchorage-dependant and –independent conditions 
 
To look closer into the effect of PKC-β inhibition on chemo-resistance, we focused 
on Enzastaurin for further experiments.  
We used the SUM159PT parental and 1uM-TR, and MB231 parental and 75nM-TR 
cell lines and treated them with different doses of Enzastaurin and measured cell 
viability over a course of 4 or 5 days. The Paclitaxel concentration used for 
SUM159PT and MB231 parental cell lines was 0.73nM and 0.46nM, respectively, 
and the resistant cells were treated with the maintenance dose of Paclitaxel. 
Expectedly, both the parental cells showed no effect, even in combination with 
Paclitaxel, but for both resistant cell lines, a dose-dependent and time-dependent 
effect is seen when Enzastaurin is given in combination with Paclitaxel (Figure 
3.6.1). Enzastaurin at 2.5μM is sufficient to significantly decrease cell viability in the 









Figure 3.6.1 The PKC-β inhibitor Enzastaurin sensitizes resistant cells to Paclitaxel in a 
dose-dependent manner 
Measurement of cell viability in SUM159PT (A) and MB231 (B) parental and resistant cell 
lines after treatment with Enzastaurin with and without Paclitaxel. The Paclitaxel concentration 
used for SUM159PT and MB23 parental cells is 0.73nM and 0.46nM, respectively, whereas for 
the resistant cells, the maintenance concentration was used. SUM159PT and MB231 cells were 
treated over a period of 4 or 5 days, respectively, with different concentrations of Enzastaurin 
with and without Paclitaxel and cell viability was measured each day. Measurements were 
normalized to Day 0 and log2 values were plotted. Paclitaxel treatment alone has no effect in 






To examine colony growth and morphology of the cells upon treatment, we 
performed a 3D colony growth assay on Matrigel and found that all the parental and 
resistant cell lines grew slightly smaller colonies when treated with Paclitaxel alone 
or Enzastaurin alone, despite only using the maintenance concentrations of Paclitaxel 
(Figure 3.6.2). This can be explained by the fact that although the cells are resistant to 
Paclitaxel, they are still undergoing selective pressure which selects for highly 
resistant cells. The combination treatment, on the other hand, has a minimal effect on 
the parental cell lines, but can dramatically reduce colony growth in the resistant cell 
lines. Moreover, for both SUM159PT and MB231, the size of the colonies grown by 
the resistant cells is smaller compared to the parental cells, which can be explained by 





Figure 3.6.2 Enzastaurin inhibits 3D colony growth in resistant cell lines in the presence 
of Paclitaxel 
Measurement of 3D growth in SUM159PT (A) and MB231 (B) parental and resistant cell lines 
after treatment with Enzastaurin and Paclitaxel. The cells were seeded on Matrigel, treated the 






We then went on to calculate the degree of re-sensitization through combination 
treatment by measuring the Paclitaxel EC50 as determined by cell viability in 
SUM159PT parental and resistant cell lines. The cells were treated for 4 days with 
increasing concentrations of Paclitaxel together with Enzastaurin at 2 different 
concentrations (1μM and 2.5μM) and cell viability was measured 4 days later. As 
expected, there was no change in the EC50 of Paclitaxel in the parental cell lines when 
Enzastaurin was combined with Paclitaxel, whereas Enzastaurin treatment drastically 
reduced EC50 in the resistant cell lines (Figure 3.6.3). Enzastaurin at both 
concentrations was able to restore EC50 similar to that in the parental cell line, 
although a slight dose-dependent effect can be seen in both resistant cell lines. At a 
concentration of 2.5μM, Enzastaurin is potent enough to reduce the EC50 by 
approximately 500-fold in both the resistant cell lines (4.7μM to 13.5nM in 500nM-
TR, and 4.9μM to 13.3nM in 1μM-TR), which is similar to the EC50 of Paclitaxel in 
















Figure 3.6.3 Enzastaurin treatment drastically reduces Paclitaxel EC50 in SUM159PT 
resistant cell lines 
A. Paclitaxel EC50 measurements in SUM159PT parental, 500nM-TR and 1μM-TR cell 
lines upon Enzastaurin treatment. The cells were treated for 24 hours with increasing 
concentrations of Paclitaxel in combination with Enzastaurin at 1μM and 2.5μM, after 
which cell viability was measured. The EC50 was calculated using Sigmoidal dose-
response and plotting the non-linear regression curve fit (Error bars show ±SD, n=6). 
B. Bar graph depicting the EC50 values of Paclitaxel in SUM159PT 500nM-TR and 






3.7. Enzastaurin reduces tumorsphere growth in Paclitaxel-resistant 
TNBC cell lines in the presence of Paclitaxel 
 
To test whether the combination treatment has any effect on the cancer stem cell side-
population, we performed a tumorsphere assay. To do so, we first seeded the 
SUM159PT and MB231 resistant cells in a 2D culture and treated them with 
Paclitaxel and Enzastaurin as single or combination treatment. Four days later, the 
dead cells were washed away and the remaining surviving cells were seeded for a 
tumorsphere assay and grown for 7 days. As seen in Figure 3.7, single treatment in 
both the resistant lines had no significant effect on the number of tumorspheres, in 
contrary, Paclitaxel treatment alone even enhanced the amount of tumorspheres in 
SUM159PT 1μM-TR. This is due to the selection the cells undergo in the presence of 
Paclitaxel. The combination treatment, however, successfully eliminated tumorsphere 
growth as seen by a significant reduction in tumorsphere number compared to the 
Paclitaxel treatment group. These results are especially interesting since the cancer 
cells are believed to be the ones surviving chemotherapy and leading to metastasis 
and disease recurrence. Finding a way to target these cells is a major challenge in 
overcoming cancer. We show here that the combination treatment of Paclitaxel with 
























Figure 3.7 Enzastaurin in combination with Paclitaxel inhibits tumorsphere growth in 
Paclitaxel-resistant cells 
Measurement of tumorsphere growth in SUM159PT 1μM-TR and MB231 75nM-TR cell lines. 
The cells were pre-treated with either single or combination treatment of Paclitaxel and 
Enzastaurin for 4 days in 2D culture. The surviving cells were then seeded in ultra-low 
attachment conditions for 7 days. They were then stained with INT o/n and the number of 
tumorspheres was counted using a GelCount. (Error bars show ±SD, n=2). 
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3.8. PKC-α inhibitors are not capable of re-sensitizing resistant cells to 
Paclitaxel 
 
It has been shown before that PKC-α plays an important role in breast cancer stem 
cells and targeting PKC-α can specifically target breast CSCs (Tam et al., 2013). This 
is due to a switch from EGFR to PDGFR signaling in CSCs which leads to the PKC-
α-dependent activation of FRA1. To test wether re-sensitization of Paclitaxel-resistant 
cells is isoform-specific, we tested different PKC-α inhibitors in an attempt to achieve 
the same re-sensitization effect as with the PKC-β inhibitors. We treated SUM159PT 
and MB231 parental and resistant cells with 2 different PKC-α inhibitors and 
measured cell viability over the course of 5 days. The two inhibitors we used, Gö-
6976 and Ro-32-0432, inhibit PKC-α with an approximately 3-fold lower IC50 
compared to PKC-β (Gö-6976: 2.3nM vs 6.2nM, Ro-32-0432: 9nM vs 28nM). Both 
inhibitors had no significant effect as single treatment in both parental and resistant 
cells in SUM159PT and MB231 (Figure 3.8.1). In addition, the parental cells were 
not effected by the combination treatment, whereas the resistant cells showed only a 
minor effect. MB231 75nM-TR showed no significant reduction in cell viability 
when PKC-α inhibitors were combined with Paclitaxel, but SUM159PT 1μM-TR 










Figure 3.8.1 PKC-α inhibitors are not able to sensitize Paclitaxel-resistant cells in the 
same manner as Enzastaurin 
Measurement of cell viability in SUM159PT (A) and MB231 (B) parental and resistant cell 
lines after treatment with the PKC-α inhibitors, Gö-6976 and Ro-32-0432, and Paclitaxel. The 
Paclitaxel concentrations used were the maintenance concentrations for the resistant cell lines 
and corresponding concentrations for the parental cell lines. The cells were treated with 2 
different PKC-α inhibitors at different concentrations and cell viability was measured each day. 






We then tested these inhibitors together with another PKC-α inhibitor, Ro-31-8220, 
in anchorage-independent conditions. SUM159PT parental and both resistant cell 
lines were seeded for a Methylcellulose assay, treated for 13 days after which they 
were stained in order to count the number of colonies. In both resistant cell lines, 
500nM-TR and 1μM-TR, there was no significant difference between inhibitor single 
treatment and in combination with Paclitaxel (Figure 3.8.2). Ro-31-8220 inhibited 
colony formation only in the parental cell lines at a high concentration, as single 
treatment and in combination with Paclitaxel. The parental cells grew slightly less 








These results show that the effect of re-sensitization in Paclitxel-resistant TNBC cell 
lines is isoform-specific. Inhibitors specifically targeting PKC-β can significantly 
reduce cell viability in 2D and 3D assays, and induce apoptosis in the presence of 
Paclitaxel, whereas PKC-α-specific inhibitors show no significant effects. Although 
PKC signaling is very broad and many PKC isoforms share similar functions, there 
are differences in the downstream targets of the various isoforms which can account 
for their different functions in Paclitaxel-resistance and re-sensitization. PKC-α  
promotes invasion of breast cancer cells and its expression correlates with tumor 
grade and poor prognosis (Lonne et al., 2010), but it has not been linked with chemo-
resistance, which is consistent with our results.   
Figure 3.8.2 PKC-α inhibitors have no effect on colony formation of SUM159PT 
Paclitaxel-resistant cells in the presence of Paclitaxel 
Measurement of colony formation in anchorage-independent conditions in a Methylcellulose 
assay of SUM159PT parental and resistant cell lines. The Paclitaxel concentrations used are the 
maintenance concentrations for the resistant cell lines and 0.73nM for the parental cell line. The 
cells were seeded for the assay and simultaneously treated with the inhibitors, Ro-31-8220, Gö-
6976 and Ro-32-0432, at 1μM, 2.5μM and 5μM. The cells were stained with INT after 13 days 
and the colonies were counted. (Error bars show ±SD, n=6). 
98 
 
3.9. PKC-β expression and protein levels in breast cancer vs. normal 
breast samples 
 
To expand the results we derived from experiments on cell lines to patient samples, 
we explored 2 different publicly available online databases. The Human Protein Atlas 
portal combines knowledge about the human proteome derived mainly from 
antibody-based methods combined with transcriptomics analysis. Higher protein 
levels of PKC-β were detected in ductal carcinoma and lobular carcinoma tissue 
samples compared to normal breast tissue (Figure 3.9 (A)). To quantify the intensity 
of the staining we then calculated the H-score for two groups: normal breast tissue vs. 
breast cancer. The H-score is calculated from the intensity of staining from each 
sample (low, medium and high) and the amount of samples of each staining intensity 
in the combined group (see MATERIALS AND METHODS 2.17). We found that the 
H-score was higher for the breast cancer samples compared to the normal breast 
tissue, strongly suggesting that PKC-β plays a role in carcinogenesis in breast cancer. 
Activation of PKC-β depends on PDK1, PLCγ, as well as DAG and Ca2+ and takes 
place at the cell membrane, after which it translocates to the cytoplasm where it can 
phosphorylate downstream targets such as GSK3β. Recent studies have shown that 
PKC isoforms in TNBC cancers can relocate to the nucleus upon activation by TGFβI 
and IL-1β, however, it is not clear what the exact mechanism behind this 
translocation and the function of PKC in the nucleus is (Paul et al., 2014). 
To get a clearer picture about the importance of PRKCB (PKC-β gene) in the 
development of breast cancer, we examined mRNA expression in Breast Ductal 
Carcinoma In Situ (DCIS) and normal breast tissue using Oncomine, a database of 
cancer transcriptome profiles. DCIS is a type of non-invasive breast cancer where 
ductal cells have undergone transformation but have not spread beyond the milk ducts 
and have not invaded into the surrounding breast tissue. Often, DCIS progresses to 
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invasive breast cancer later on. As seen in Figure 3.9 (B), PRKCB mRNA levels were 
significantly higher in Breast DCIS compared to normal  breast in the Ma Breast 4 
dataset. We also examined the expression levels of GSK3B, a direct downstream 
target of PRKCB, which follows the same trend as PRKCB and also has significantly 
higher mRNA levels in Breast DCIS. We then wanted to explore PRKCB expression 
in the stroma of invasive ductal breast tumors, as stroma is an important player in 
tumor formation, invasion and metastasis. The bulk of stroma surrounding tumors are 
cancer-associated fibroblasts (CAFs) that are activated by cancer cells and have been 
shown to induce EMT in breast cancer cells through paracrine TGF-β signaling (Yu 
et al., 2014). In addition, one study found that PKC-β is up-regulated in the tumor 
microenvironment in mouse mammary tumor virus-polyoma middle T-antigen 
(MMTV-PyMY) induced mammary tumorigenesis (Wallace et al., 2014). When PKC-
β was diminished in the stromal compartment, the mice formed smaller tumors with 
diminished collagen deposition. In concordance with these results, we found that 
PRKCB was also increased in the stroma of invasive ductal breast carcinoma patient 
samples compared to normal breast samples in the Karnoub dataset (Karnoub et al., 
2007).  
These results suggest that PKC-β plays an important role in the development of breast 
cancer, as well as in established ductal and lobular carcinoma.  








   
Figure 3.9 PKC-β is highly expressed in breast cancer compared to normal breast tissue 
in patient samples and cell lines 
A. The Human Protein Atlas. Patient samples (n=6) were stained with anti-PKC-β 
antibodies in normal breast tissue, and ductal and lobular carcinoma of the breast 
(n=28). Sample staining is shown for each group. The H-score was calculated 
according to the staining intensity given by the database. To calculate the H-score the 
staining intensity of each sample (1,2 or 3 for increasing intensity) was multiplied 
with the percentage of samples in each intensity group and all 3 values were added 
together. This calculation was performed for normal breast tissue and breast cancer 
samples separately. 
B. Oncomine. PRKCB and GSK3B expression are shown in Breast DCIS (GSK3B and 
PRKCB: n=11) compared to normal breast tissue (GSK3B and PRKCB: n=14) (Ma 
Breast dataset), and in the stroma of invasive ductal breast carcinoma (n=7) compared 




3.10. Mechanism of PKC-β signaling in resistance and upon sensitization 
 
To understand how the inhibition of PKC-β can re-sensitize cells to Paclitaxel once 
they have acquired resistance, we examined the modulation of signaling pathways 
upon PKC-β inhibition. We first treated MB231 parental cells with increasing 
concentrations of Enzastaurin for 24 and 48 hours and found no change in the total 
protein levels of PKC-β, but phosphorylation of GSK3β on Serine 9 (GSK3βSer9) was 
diminished (Figure 3.10 (A)). GSK3β is directly phosphorylated by PKC-β (Goode et 
al., 1992), and is a reliable pharmacodynamic marker for Enzastaurin activity 
(Miranda et al., 2015). Serine 9 phosphorylation leads to inactivation of its kinase 
activity, therefore PKC-β inhibits GSK3β activity. Phosphorylation of PKCs is not a 
reliable marker for its activation and activity as they don’t require phosphorylation of 
the enzyme. Rather translocation of the protein to different cellular compartments 
induced by upstream signaling is a reliable marker for monitoring its activity (Rosse 
et al., 2010).  
When we subjected SUM159PT and MB231 parental and resistant cell lines to single 
treatment with 2.5μM Enzastaurin or combination treatment with Paclitaxel, we 
found similar results. We examined phosphorylation of PKC-β at Thr641 which 
mediates its binding to Hsp70 thereby regulating its stability and phosphorylation. 
Thr641 is also needed for the catalytic function and autophosphorylation of PKC-β. 
Protein levels of Thr641-phosphorylated PKC-β remained unchanged in all treatment 
groups, but GSK3βSer9 was diminished upon Enzastaurin treatment in all cell lines 
(Figure 3.10 (B)). Moreover, GSK3βSer9 basal levels were slightly lower in the 
resistant cell lines compared to the parental cell lines in the DMSO treatment groups, 
suggesting that GSK3β is over-activated and could be directly involved in chemo-
resistance as part of the PKC-β signaling cascade. We examined Mcl-1 protein levels 
in order to deterimine its role in apoptosis of resistant cell lines upon combination 
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treatment. It has been published earlier that the pro-survival protein Mcl-1 plays a 
crucial role in regulating apoptosis upon treatment with spindle poisons (Wertz et al., 
2011). Mcl-1 is directly phosphorylated by GSK3β on Serine 159 (Maurer et al., 
2006) and when phosphorylated, it can interact with the tumor-suppressor FBW7, the 
substrate-binding component of a ubiquitin-ligase complex, which leads to its 
ubiquitinylation and degradation. As seen below, Mcl-1 is degraded only in the 
resistant cell lines when treated with Paclitaxel and Enzastaurin. Interestingly, 
treatment with Enzastaurin alone has no effect on Mcl-1 levels in either the parental 
or resistant cell lines.  
These results show that Enzastaurin acts by inhibiting the inhibitory Serine 9 
phosphorylation on GSK3β which activates GSK3β, and in turn leads to Mcl-1 










Figure 3.10 Western blot analysis of down-stream signaling of Enzastaurin treatment on 
PKC-β, GSK3β and Mcl-1 in SUM159PT and MB231 
Cells were treated for 24 hours and then harvested for western blot analysis. 
A. MB231 parental cells were subjected to treatment with increasing concentrations of 
Enzastaurin. At high concentrations, total PKC-β levels were slightly reduced, but 
GSK3βSer9, a pharmacodynamic marker for Enzastaurin activity, was completely 
diminished in all treatment groups. 
B. SUM159PT and MB231 parental and both resistant cells were subjected to 24 hour 





3.11. GSK3β inhibitors recapitulate the effect of re-sensitization by 
Enzastaurin 
 
We used a GSK3β inhibitor and an activator to investigate whether the inhibition of 
GSK3βSer9 downstream of PKC-β can also re-sensitize resistant cells to Paclitaxel, or 
if it is merely a side-effect of Enzastaurin treatment. SB216763 has the same effect on 
GSK3β Serine 9 phosphorylation as Enzastaurin. It acts as a GSK3β “activator” and 
diminishes GSK3βSer9 phosphorylation. Lithium Chloride (LiCl), on the other hand, 
has the opposite effect and inhibits GSK3β by increasing Serine 9 phosphorylation 
levels. The mechanism by which LiCl inhibits GSK3β is unclear but there are 2 
proposed mechanisms: 1) it is a competitive inhibitor with regards to Mg2+; 2) it 
inhibits potassium deprivation, which would otherwise lead to dephosphorylation of 
GSK3β (Kramer et al., 2012). We treated MB231 parental and 75nM-TR resistant 
cells with these inhbititors alone or together with Paclitaxel for 24 hours to examine 
GSK3βSer9 levels. As seen in the western blot below, SB216763 successfully inhibits 
GSK3β phosphorylation in both cell lines, whereas LiCl leads to increased levels of 
phosphorylated GSK3β (Figure 3.11.1). These results are consistent with previously 
published data  (Tan et al., 2005). Other activating phosphorylation sites of GSK3β 
show no change after treatment with the inhibitors alone or in combination with 
Paclitaxel. Mcl-1 levels remain unchanged in all the treatment groups in the parental 
cell lines, whereas they are slightly reduced in the combination treatment groups in 








We then performed an anchorage-independent Methylcellulose assay to examine the 
effect of the GSK3β inhibitors in 3D growth conditions in SUM159PT parental and 
1μM-TR, and MB231 parental and 75nM-TR cell lines. The cells were treated for 13 
days with 4 different inhibitors: 3 GSK3β “activators” (BIO, A1070722 and 
SB216763) at 2.5μM and 5μM each, and one GSK3β inhibitor (LiCl) at 1mM and 
2mM. The colonies were then stained with INT and counted.  
In SUM159PT and MB231 parental cell lines, none of the inhibitors showed a 
decrease in colony formation in the combination treatment groups compared to single 
treatment with the inhibitors alone (Figure 3.11.2). However, SUM159PT 1μM-TR 
cell line showed significant  dose-dependent reduction in colony formation when 
treated with the 3 GSK3β “activators” in the presence of Paclitaxel, whereas LiCl, the 
true GSK3β inhibitor, had no effect on colony formation, even when Paclitaxel was 
added. The results for MB231 75nM-TR cell line are not so conclusive because the 
Figure 3.11.1 Western blot analysis of the effect of GSK3β inhibitors in MB231 parental 
and resistant cells 
MB231 parental and 75nM-TR cell lines were treated with SB216763 (5μM) and LiCl (2mM) 
alone or in combination with Paclitaxel for 24 hours and then harvested for western blot 
analysis. Paclitaxel was used at 0.46nM for the parental and 75nM for the resistant cell line. 
SB216763 diminished GSK3βSer9, similar to Enzastaurin, whereas LiCl slightly increased 
protein levels.  
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Paclitaxel only treated group showed reduced colony formation compared to the 
DMSO treatment group, which is unexpected. This could be because in general, the 
MB231 cells are not able to grow and form distinct colonies when seeded together 
with Methylcellulose on the Bacto-Agar. The colonies formed by these cells are 
“loose” and the cells seem to disperse, so the software used to count the colonies may 
not give reliable results.  
These results shows that GSK3β “activators”, which have the same effect on 





To determine wether the treatment with GSK3β compounds can induce apoptosis in 
the presence of Paclitaxel, we treated SUM159PT 1μM-TR and MB231 75nM-TR 
Figure 3.11.2 A set of GSK3β inhibitors reduce colony formation in the resistant cells in the 
presence of Paclitaxel  
Anchorage-independent Methylcellulose assay was used to determine colony formation in 
SUM159PT parental and 1μM-TR, and MB231 parental and 75nM-TR cell lines after treatment 
with various GSK3β inhibitors. The cells were treated for 13 days with different inhibitors alone 
or in combination with Paclitaxel and, subsequently, stained with INT o/n before the colonies 
were counted. (Error bars show ±SD, n=6). 
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cell lines with either SB216763 or LiCl alone or in combination with Paclitaxel for 4 
days and performed cell cycle analysis using PI staining. Since we know that 
Enzastaurin in combination with Paclitaxel can induce cell death in both cell lines, as 
determined by an increase in the SubG1 population, we used this as our positive 
control. The combination of SB216763 and Paclitaxel has a very similatr effect in the 
SUM159PT resistant cell lines where the amount of cell death is almost identical to 
the positive control (Figure 3.11.3 (A)). Surprisingly, the MB231 resistant cell line 
showed a much more modest increase in the SubG1 population compared to 
Paclitaxel treatment alone. One reason could be that SB216763 was not able to 
completely deplete GSK3βSer9 protein levels in this cell line, as determined by 
western blot analysis (see Figure 3.11.1). As expected, LiCl does not increase cell 
death in combination with Paclitaxel in either of the cell lines when compared to the 
Paclitaxel treatment group alone.  
Although the amount of SubG1 in the GSK3β “activator” + Paclitaxel treatment 
group in MB23 75nM-TR is much lower than the Enzastaurin + Paclitaxel treatmen 
group, the number of floating cells in the wells, which represent cells that are most 









This data suggests that GSK3β plays an important role in chemo-resistance and 
activation of GSK3β can re-sensitize cells to Paclitaxel. This could be the reason for 
the effectiveness of Enzastaurin in re-sensitization, as GSK3β is directly downstream 





Figure 3.11.3 GSK3β activation leads to increased cell death in the resistant cells in the 
presence of Paclitaxel 
A. Measurement of SubG1 fraction in the SUM159PT and MB231 resistant cell lines 
after 4 days of treatment with SB216763 (5μM) and LiCl (2mM) as single treatment 
or in combination with Paclitaxel. The Paclitaxel concentration used is 1μM and 
75nM for the SUM159PT and MB231 resistant cell lines, respectively. (Error bars 
show ±SD, n=3). 
B. Microscope images of different treatment groups in SUM159PT and MB231 cell lines 




3.12. Paclitaxel-resistant cell lines exhibit cross-resistance to other 
chemotherapeutic compounds 
 
Vincristine (VCR) is a spindle poison that belongs to the same class of 
chemotherapeutic drugs as Paclitaxel, although its effect on microtubule stability is 
opposite. While Paclitaxel binds to tubulin and promotes microtubule stabilization, 
VCR binds to tubulin dimers, thereby inhibiting microtubule assembly. Both drugs 
lead to cell cycle arrest in the mitotic phase, but cells treated with VCR arrest in the 
prometaphase. Due to the missing spindle tubules in these cells, the kinetochores 
remain unattached and the SAC remains inactive, leading to mitotic arrest (Rudner 
and Murray, 1996).  
When tested whether Paclitaxel-resistant cells showed cross-resistance to VCR, we 
found that, indeed, the resistant cells lines are also more resistant to VCR, compared 
to the parental cell lines, as measured by their EC50 (Figure 3.12.1 (A)). SUM159PT 
Paclitaxel-resistant cell lines exhibit a 1000-fold increase in the EC50 compared to the 
parental cell lines (3.62μM vs. 3.17nM), whereas the shift in EC50 of VCR is less 
drastic in the MB231 resistant cells compared to parental (23.21nM vs. 3.01nM). In 
both resistant cell lines, however, Enzastaurin is able to restore VCR-sensitivity and 
reduce the EC50 similar to those of the parental cells.  
To examine whether Enzastaurin can induce apoptosis in the resistant cell lines upon 
VCR treatment, we treated cells with increasing concentrations of VCR and measured 
the amount of SubG1 population as a measure of apoptosis (Figure 3.12.1 (B)). 
Although VCR alone could induce small amounts of apoptosis, there is a significant 
increase in apoptotic cells in both resistant cell lines when Enzastaurin is added to 
VCR treatment. Therefore, Enzastaurin is able to restore VCR-sensitivity in the 









We also included another chemotherapeutic drug, Adriamycin, which is not a spindle 
poison and targets cells through a different mechanism, in order to determine whether 
re-sensitization with Enzastaurin is dependent on mitotic arrest. It is routinely used 
for the treatment of a number of different cancers such as breast, gastric and ovarian 
cancers, sarcoma and mutiple myeloma (Cortes-Funes and Coronado, 2007, Weiss, 
Figure 3.12.1 Paclitaxel-resistant cells exhibit cross-resistance to Vicristine which can be 
reversed with Enzastaurin 
A. Paclitaxel EC50 measured by cell viability assay in SUM159PT parental and 1μM-TR, 
and MB231 parental and 75nM-TR cell lines. The cells were treated for 4 days before 
cell viability was measured. (Error bars show ±SD, n=6) 
B. Percentage of SubG1 fractions after 4 days of treatment in SUM159PT 1μM-TR and 
MB231 75nM-TR cell lines with different concentrations of Vincristine (0.1μM, 1μM 
and 5μM for SUM159PT 1μM-TR, and 1nM, 10nM and 100nM for MB231 75nM-TR) 
with and without Enzastaurin (2.5μM). (Error bars show ±SD, n=3, **: p-value <0.01, 





1992). Adriamycin (ADR) is an anthracycline, it intercalates into the DNA and 
inhibits topoisomerase II, an enzyme that detangles and relaxes DNA supercoils 
(Tewey et al., 1984). Another mechanism of action has been proposed which includes 
the generation of free radicals that cause damage to the cellular membranes and DNA 
(Gewirtz, 1999). By inhibiting topoisomerase II, the DNA chain which has been 
broken for replication, will not be released and the cells are unable to undergo 
mitosis.  
Paclitaxel-resistant SUM159PT and MB231 cells also show higher resistance to ADR 
compared to the parental cell  lines, as determined by an approximate 1000-fold 
increase in the EC50 to ADR (Figure 3.12.2 (A)). However, Enzastaurin is only partly 
able to restore ADR-sensitivity in SUM159PT, but not in the MB231 resistant cell 
line. When we determined the SubG1 fraction in single and combination treatment 
groups, we found that althoug ADR can reduce ADR EC50 in SUM159PT resistant 
cell line, it is unable to induce significantly higher levels of apoptosis in combination 
with Paclitaxel (Figure 3.12.2 (B)). In MB231 75nM-TR, the increase in apoptotic 
cells is also not sighnificant in the combination vs. single treatment group. This is 
likely due to the difference in their chemo-toxic effects. This data suggests that 
Enzastaurin is only able to significantl restore sensitivity for drugs that induce mitotic 














Figure 3.12.2 Paclitaxel-resistant cells exhibit cross-resistance to Adriamycin 
A. Paclitaxel EC50 measured by cell viability assay in SUM159PT parental and 1μM-TR, 
and MB231 parental and 75nM-TR cell lines. The cells were treated for 4 days before 
cell viability was measured. (Error bars show ±SD, n=6). 
B. Percentage of SubG1 fractions after 4 days of treatment in SUM159PT 1μM-TR and 
MB231 75nM-TR cell lines with different concentrations of Adriamycin (0.1μM, 









3.13. Enzastaurin can restore mitotic arrest in resistant cells upon 
treatment with Paclitaxel 
 
In order for Paclitaxel to be effective, the cells must undergo cell division and reach 
mitosis. Paclitaxel then leads to stabilization of mitotic microtubules and, 
subsequently, mitotic arrest. It has been found that Paclitaxel-induced cell death is 
dependent on the activation of the spindle assembly checkpoint (SAC), and the 
suppression of Mad2 and BubR1, two important checkpoint genes, results in higher 
resistance to Paclitaxel (Sudo et al., 2004).  
3.13.1. Paclitaxel-induced mitotic arrest and cell death in sensitive cell lines 
 
To validate these results in our cell lines, we treated MB231 parental cell lines with 
Paclitaxel and used an anti-phospho-Histone H3 (p-H3) antibody to detect cells in the 
mitotic phase. We found that upon treatment with Paclitaxel for 24 hours, 16.87% of 
the cells were arrested in the mitotic phase compared to only 1.5% in untreated 
conditions, and at 48 and 72 hours, this population decreased dramatically, 
accompanied by an increase in the number of multinucleated cells (Figure 3.13.1 
(A)). This can be explained by the fact that cells arrested in the mitotic phase can 
undergo different fates. One consequence of mitotic arrest is mitotic cell death, but 
cells that can overcome mitotic arrest can slip into the next interphase (mitotic 
slippage), or undergo one round of aberrant mitosis. As correct mitosis is not 
possible, the cells become tetraploid and will eventually undergo senescence or cell 
death (Vitale et al., 2011). Additionally, we observed an increase in the number of 
apoptotic cells from 24 to 72 hours determined by the SubG1 population, indicating 
that most of the tetraploid cells and those arrested in the mitotic phase, do in fact 










To look closer into the mechanism of cell death upon treatment with Paclitaxel, we 
treated SUM159PT and MB231 parental cells with increasing concentrations of 
Figure 3.13.1 Paclitaxel induces mitotic arrest and subsequent cell death in MB231 parental 
cells 
A. MB231 parental cells were treated for 24, 48 and 72 hours with 50nM Paclitaxel before 
they were harvested and stained with Propidium Iodide and anti-pH3 antibody. FACS 
analysis was performed measuring DNA content and intensity of p-H3 staining. 
B. MB231 parental cells were treated for 24, 48 and 72 hours with 50nM Paclitaxel, then 
harvested, fixed and stained with Propidium Iodide. FACS analysis was performed to 
measure SubG1 population in the different treatment groups. (n=1). 
C. Bar graph depicting percentages of SubG1 after Paclitaxel treatment as determined by 












Paclitaxel and performed western blot to detect changes in signaling pathways. The 
cells were harvested at 24 hours when most of the affected cells are still arrested in 
the mitotic phase. We found that Aurora B levels are increased, especially in 
SUM159PT cells, which is due to the activation of the SAC in the mitotic phase 
(Figure 3.13.2 (A)). It is believed that unattached kinetochores lead to an 
accumulation of Aurora B at the centromeres of chromosomes in the metaphase plate 
and Aurora B is stabilized when there is a lack of tension from the microtubules 
between the sister chromatids (Musacchio and Salmon, 2007). This is consistent with 
the fact that Paclitaxel arrests cells in the mitotic phase inhibiting tension on the 
chromatids. Furthermore, levels of phosphorylated C-Raf are higher in the Paclitaxel 
treated samples, and it has been shown that C-Raf phosphorylation is a requirement 
for Paclitaxel-induced apoptosis (Blagosklonny et al., 1996). C-Raf, when activated, 
can post-translationally phsophorylate Mcl-1, which leads to its ubiquitination and 
subsequent proteasome-mediated degradation. Mcl-1 downregulation correlates with 
increased levels of Poly(ADP-ribose) polymerase (PARP) cleavage, one of the main 
cleavage targets of Caspase 3 and a marker for cells undergoing apoptosis.  
We then went on to determine whether the inhibition of Aurora B could abolish 
Paclitaxel-induced cell death. To do so, we treated SUM159PT and MB231 parental 
cells with the Aurora B inhibitor VX-680, a potent and highly selective Aurora 
Kinase inhibitor. As expected, we found that treatment with VX-680 could abolish 
cell death in Paclitaxel-treated cells up to appromximately 70% in the MB231 
parental cells (Figure 3.13.2 (B)). The effect in SUM159PT cells is milder but 
remains notable with approximately 40% reduction. As seen in the microscope 
images, Paclitaxel treated cells evidently undergo cell death with an increase in the 
number of floating cells, whereas the addition of VX-680 can rescue apoptosis 









These results show that Aurora Kinases B is upregulated upon Paclitaxel treatment of 
parental Paclitaxel-sensitive cells, and that inhibition of Aurora Kinases partly 
inhibits Paclitaxel-induced cell death. 
 
Figure 3.13.2 Up-regulation of Aurora Kinase B is crucial for Paclitaxel-induced cell 
death 
A. SUM159PT and MB231 parental cells were treated with increasing concentrations of 
Paclitaxel (Taxol) for 24 hours and downstream signaling was determined using 
western blot analysis. 
B. SUM159PT and MB231 parental cells were treated with 50nM Paclitaxel alone or in 
combination with the Aurora Kinase inhibitor (VX-680) at 1μM for 4 days and then 
harvested for FACS analysis. The SubG1 fraction was determined to detect the 
amount of cell death. (n=1). 





3.13.2. Paclitaxel-resistant cells over come mitotic arrest by down-regulating 
Aurora Kinases 
 
We then investigated the effect of Paclitaxel and Enzastaurin treatment on signaling 
in the resistant cells, especially in terms of Aurora Kinase activation. As seen in 
Figure 3.13.3, we found that C-Raf is increasingly phosphorylated upon combination 
treatment, more so in SUM159PT resistant cells. As expected, this treatment group 
also shows increased levels of cleaved PARP, indicative of apoptosis. Aurora B 
levels are lower in both resistant cell lines compared to their parental counterpart. 
However, combination treatment of Enzastaurin and Paclitaxel is able to restore 
Aurora B levels, whereas single treatment alone has no effect. These findings are 
similar to Aurora A, however the increase in protein levels upon combination 
treatment are not as striking in MB231 resistant cell lines. Moreover, Aurora A levels 
in the MB231 resistant cell line are similar to the parental cell line. These results 
suggest that Enzastaurin treatment can restore SAC activation and mitotic arrest in 
the resistant cell lines in the presence of Paclitaxel, by restoring accumulation and 

















Figure 3.13.3 Enzastaurin restores levels of Aurora Kinase B in resistant cell lines upon 
treatment with Paclitaxel 
SUM159PT parental and 1μM-TR, and MB231 parental and 75nM-TR cell lines were treated 
with Paclitaxel or Enzastaurin (2.5μM) alone, and in combination. Paclitaxel was used at 
0.73nM and 1μM for SUM159PT parental and resistant cell lines, and 0.46nM and 75nM for 
MB231 parental and resistant cell lines. Cells were harvested after 24 hours and levels of 
protein were detected using western blot analysis. 
A.  Protein levels detected by western blotting. The blots were incubated with antibodies 
targeting Serine 388-phosphorylated C-Raf, cleaved PARP, Aurora kinase A and B. 
B. Quantification of Aurora kinase B bands detected by western blotting. Image Lab 4.1 
software was used to quantify bands relative to the DMSO control of the parental cell 





We then dived further into elucidating the function of Aurora Kinases in re-
sensitizing resistant cells to Paclitaxel. To do so, we screened various Aurora Kinase 
inhibitors in the resistant cell lines in order to determine whether these can rescue 
cells when treated with Paclitaxel and Enzastaurin. If the addition of an Aurora 
Kinase inhibitor to the combination treatment can inhibit cell death in resistant cell 
lines, the we can conclude that Aurora Kinases are required for the re-sensitization 
effect. This, in turn, suggests that cell death upon combination treatment is a result of 
mitotic arrest induced by Paclitaxel due to Enzastaurin.  
We found that out of all the Aurora Kinase inhibitors we used (VX-680, TAK901, 
AZD1152-HQPA, MLN8237, and ZM447439), VX-680 could rescue combination 
treatment effect in all the 4 resistant cell lines while having minimal effect on cell 
viability when used as single treatment (Figure 3.13.4 (A)). In general, all the 
inhibitors showed a more significant rescue effect in the MB231 resistant cell lines, 
whereas VX-680 had the strongest effect in SUM159PT resistant cells. VX-680 
(Tozasertib) is a potent and selective small-molecule inibitor of the Aurora Kinases 
with apparent inhibition constants (Ki(app)) of 0.6nM, 18nM and 4.6nm for Aurora 










Figure 3.13.4 Various Aurora Kinase inhibitors can rescue cell death upon combination 
treatment of Paclitaxel with Enzastaurin in Paclitaxel-resistant cell lines 
A. SUM159PT and MB231 resistant cell lines were treated with various Aurora Kinase 
inhibitors alone or in combination with Paclitaxel and Enzastaurin. Aurora Kinase 
inhibitors were all used at 1μM and 5μM. Cell viability was measured at Day 0 and 
Day 4. Dat 4 measurements were normalized to Day 0 measurements and plotted 
(Error bars show ±SD, n=6). 
B. Table listing Aurora Kinase inhibitors with the respective Ki (inhibitory constant) 





To show that, indeed, the Aurora Kinase Inhibitor VX-680 can inhibit cell cycle 
arrest in the resistant cell lines upon combination treatment, we performed p-H3 
staining of the different treatment groups at 24, 48 and 72 hours in MB231 75nM-TR. 
We found that the resistant cell line does not undergo mitotic arrest in the presence of 
Paclitaxel, as do the parental chemo-sensitive cell lines, as shown earlier. However, 
when Enzastaurin is added to the Paclitaxel treatment, mitotic arrest is restored in the 
resistant cell lines, as seen by an increase in the number of p-H3+ cells from 2.65% 
(Paclitaxel treatment only) to 34.51% (combination treatment) (Figure 3.13.5). 
Enzastaurin treatment alone has no effect on the mitotic phase. At later time points, 
48 and 72 hours, the cells that have arrested in the mitotic phase become 
multinucleated, as suggested by a 4N DNA content. They remain pH3-positive, 
therefore they are in the mitotic phase, due to the effect of Paclitaxel, which stabilizes 
microtubules. We showed earlier that VX-680 can rescue decreased cell viability 
upon combination treatment, and here we show that this is due to the inhibition of cell 
cycle and mitotic arrest. Addition of VX-680 to the combination group depletes 
mitotic arrest upon combination treatment. When the resistant cells fail to activate the 













Figure 3.13.5 Aurora Kinase B inhibition rescues cell death upon re-sensitization of 
Paclitaxel-resistant cells by Enzastaurin 
Cells were treated for 24, 48 or 72 hours with 75nM Paclitaxel, 2.5μM Enzastaurin, and 1μM 
VX-680 in different combination groups. They were then stained with anti-phospho-H3 
antibody and FACS analysis was performed.  
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3.14. Aurora B levels negatively correlate with Paclitaxel sensitivity in a 
panel of basal-like breast cancer cell lines 
 
As shown earlier, Aurora B and partially Aurora A levels are downregulated in the 
resistant compared to the parental cell lines, therefore we went on to explore whether 
there is a correlation between Aurora Kinase expression and Paclitaxel sensitivity in a 
panel of basal and luminal breast cancer cell lines and the normal breast epithelial cell 
line MCF10A. Aurora Kinase B (AURKB) and A (AURKA) expression levels were 
obtained from the Neve et al. dataset on Gene Expression-Based Outcome for Breast 
Cancer Online (GOBO) (Neve et al., 2006), where they performed transcription 
profiling of a panel of 51 breast cancer cell lines. We measured Paclitaxel EC50 in all 
cell lines using cell viability assay. We then plotted both sets of data on a scatter plot 
with AURKB/A expression on the y-axis and Paclitaxel EC50 on the x-axis. As seen 
in Figure 3.14, there is no significant correlation between AURKB expression and 
EC50 when all the cell lines are combined. However, when we selected only for the 
basal breast cancer cell lines, the correlation is highly significant, with an R2 
coefficient of determination of 0.8411 (p-value=0.0013). This suggests that Aurora B 
plays an important role in Paclitaxel-sensitivity, which can be attributed to its 
function in mitotic spindle attachment and mitotic arrest. 
We went on to determine whether Aurora A levels also determine sensitivity to 
Paclitaxel, as Aurora A plays an important role in early mitosis (prophase) in 
regulating correct function of the centrosomes. Interestingly, we found no correltation 
between AURKA expression and Paclitaxel EC50 in all of the breast cancer cell lines, 













Figure 3.14 Aurora Kinase B expression negatively correlates with Paclitaxel sensitivity in 
a panel of basal breast cancer cell lines 
AURKB/A expression values were obtained from Neve et al. dataset (Neve et al., 2006) from 
Gene Expression-Based Outcome for Breast Cancer Online (GOBO). Transcription profiling 
was performed using A-AFFY-33-Affymetrix GeneChip Human Genome HG-U133A [HG-
U133A]. Expression values were obtained by performing Robust Micro-Array Average (RMA) 
normalization and the values were Log2 transformed. AffyID for AURKB: 209464_at, AffyIDs 
for AURKA: 208079_s_at and 204092_s_at. Paclitaxel EC50 was measured using cell viability 
assay. Cells were treated for 4 days with increasing concentrations of Paclitaxel (n=6).  
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3.15. Targeted siRNA knock-down of Aurora B inhibits re-sensitization of 
Paclitaxel-induced mitotic arrest 
 
To further examine whether the rescue effect seen with VX-680 is specific to the 
Aurora B isoform, we performed siRNA-based knock-down of AURKB. We 
knocked-down Aurora B using 2 different siRNA sequences (siAurB (Pre) and 
siAurB) in SUM159PT parental and 1μM-TR, and MB231 parental and 75nM-TR 
cell lines. 24 hours after knock-down we seeded the cells to measure cell viability 
over a course of 5 days with different treatment groups. As seen in the Figure 3.28 
(A), both siRNA sequences are able to significantly rescue cell viability in the 
MB231 parental cell lines upon Paclitaxel treatment at 5nM and 50nM. However, the 
effect is milder in SUM159PT parental cells lines, which is not surprising as the basal 
levels of Aurora B mRNA expression are lower in SUM159PT compared to MB231 
cell lines (Figure 3.15.1 (C)). This trend can further be explained by Paclitaxel 
sensitivity of both cell lines, as SUM159PT is intrinsically more resistant to 
Paclitaxel compared to MB231. 
In case of the resistant cell lines, siRNA knock-down of Aurora B significantly 
rescued cell viability upon combination treatment in SUM159PT 1μM-TR (only 
siAurB (Pre)) and MB231 75nM-TR (Figure 3.15.1 (B)). Again, the rescue effect is 
stronger in MB231 resistant cell lines compared to SUM159PT resistant cell lines due 
to the higher levels of AURKB mRNA (Figure 3.15.1 (C)) . When the mRNA levels 
are already very low, as in SUM159PT cells, it is no surprise that the knock-down 
effect is weak. In general, resistant cell lines have lower levels of AURKB mRNA 
and this is in agreement with the database results showing a negative correltation 


















To examine whether this rescue effect is due to the inability of mitotic arrest and SAC 
activation as a result of Aurora Kinase B knock-down, we performed cell cycle 
analysis. We treated MB231 parental and 75nM-TR cells with combination treatment 
for 24 hours after knock-down and performed pH3-staining. Our results replicate our 
findings using the Aurora Kinase inhibitor VX-680. SiRNA-based knock-down of 
Aurora Kinase B abolished mitotic arrest after Paclitaxel treatment in the parental cell 
lines, and after combination treatment in the resistant cell lines (Figure 3.15.2).  
Figure 3.15.1 Aurora Kinase B is crucial for Paclitaxel-induced inhibition of cell viability 
in parental and resistant SUM159PT and MB231 cell lines 
A. siRNA knock-down of Aurora B in SUM159PT and MB231 parental cell lines. Two 
siRNA sequences were used to knock-down Aurora B in the cell lines (siAurB (Pre) 
and siAurB) at a concentration of 40nM. 24 hours after siRNA treatment, cells were 
re-seeded treated with 5nM or 50nM Paclitaxel and cell viability was measured over 
a course of 5 days and normalized to the DMSO control. (Error bars show ±SD, n=6, 
****:p-values<0.0001). 
B. siRNA knock-down of Aurora B in SUM159PT 1μM-TR and MB231 75nM-TR. 
Two siRNA sequences were used to knock-down Aurora B at a concentration of 
40nM. After 24 hours, the cells were re-seeded and treated with DMSO, or 2.5μM 
Enzastaurin + Paclitaxel 1μM or 75nM in SUM159PT 1μM-TR and MB231 75nM-
TR, respectively. Cell viability was measured over a course of 5 days and 
measurements were normalized to the DMSO control. (Error bars show ± SD, n=6, 
****:p-values<0.0001). 
C. Validation of Aurora B knock-down. 48 hours after siRNA treatment, cells were 
harvested and Aurora B (AURKB) mRNA levels were determined using Realtime-
PCR.mRNA expression values were normalized to Actin (ACTB) (Error bars show 








These results suggest that Enzastaurin can restore Paclitaxel-induced mitotic arrest in 








Figure 3.15.2 Aurora Kinase B abolished Paclitaxel-induced mitotic arrest 
p-H3 staining of MB231 parental and 75nM-TR cell lines after Aurora B siRNA knockdown. 
Cells were treated with two different siRNA sequences targeting Aurora Kinase B (siAurB 
(Pre) and siAurB) at a concentration of 40nM. 24 hours later, the cells were re-seeded and 
treated with Paclitaxel alone (parental) or Paclitaxel + Enzastaurin (resistant) and p-H3 staining 
































4.1. Enzastaurin: mechanism of Paclitaxel-sensitization 
 
The exact mechanism by which Enzastaurin inhibits cell viability is still unclear. 
Enzastaurin was originally synthesized as a Protein Kinase C (PKC) β-specific 
inhibitor based on the structure of Staurosporine, a natural compound which is a 
potent inhibitor of PKC but has limited selectivity for ATP-dependent kinases and 
individual PKC isozymes in vitro (Faul et al., 2003). Moreover, PKCs regulate ATP-
binding cassette sub-family B member 1 (ABCB1). Interestingly, it was found that 
Enzastaurin could sensitize ABCB1-expressing Vincristine-resistant neuroblastoma 
and rhabdomyosarcoma cells, while having minimal effect on the cell viability of 
non-resistant cells (Michaelis et al., 2015). It was suggested that Enzastaurin directly 
interacts with ABCB1 and inhibits ABCB1 ATPase activity, rather than through 
PKC, as determined by docking studies. Moreover, siRNA-targeted knock-down of 
PKC-β, but not PKC-α, could inhibit the efflux pumping mechanism of ABCB1. 
Other studies show that PKC-α and -β can directly phosphorylate and regulate 
ABCB1, although this seems to be cell type specific. It was found that in ovarian 
cancer cells PKC-α and PKC-β knock-down could reverse ABCB1-mediated multi 
drug resistance and Taxol-resistant cells (Masanek et al., 2002).  
In the SUM159PT Paclitaxel-resistant cells lines we have generated, we found a 
notable increase in the ABCB1 expression when compared to the parental cells as 
determined by microarray analysis (Figure 4.1). Although many of the ABC 
transporters show increased expression in the resistant cell lines, ABCB1 expression 
is the most distinguished. Therefore, the effect of re-sensitization to Paclitaxel 
through Enzastaurin treatment could be due to its direct or indirect inhibition of 








ABCB1, also known a P-glycoprotein (P-gp) or multidrug resistance protein 1 
(MDR1), is phosphorylated by PKCs and PKA at the serine residues in its linker 
region (Chambers et al., 1994). Some have even suggested that these 
phosphorylations are required for the translocation and activation of ABCB1 
(Germann et al., 1996). There are 3 PKC-mediated phosphorylation residues at 
Ser661, Ser667 and Ser671, and 3 PKA-mediated phosphorylation residues at Ser667, 
Ser671 and Ser683, and all of them are in the intracellular linker region anchoring the 
ABCB1 protein in the cellular membrane. Interestingly, the 2 classes of inhibitors 
which showed the greatest effect in the kinase inhibitor screen on our Paclitaxel-
resistant cell lines were PKC and PKA inhibitors. We decided to focus on PKC-β for 
this project as these inhibitors induced slightly higher levels of apoptosis in the cell 
lines in combination with Paclitaxel, and PKC-β inhibitors are already being used in 
clinical trials. However, the kinase screen revealed an important role for PKA in 
Figure 4.1 Increased expression of ABC transporters in Paclitaxel-resistant SUM159PT 
cell lines 
Microarray analysis was performed to determine gene expression changes in Paclitaxel-
resistant SUM159PT 500nM-TR and 1μM-TR cell lines compared to the parental cell line. 
Quantile normalization was performed and after fold change cut-off =2 and FDR<0.05, the list 
of significantly over-expressed genes was obtained. The graph shows the log2 gene expression 




Paclitaxel-resistance, similar to PKC-β, which could be due to its role on ABCB1 
phosphorylation and activation. 
Moreover, the Enzastaurin concentration of 2.5μM, which we have used for all the 
experiments in this study, did not lead to a reduction in the phosphorylation levels of 
PKC-β (Figure 3.10). 
These results suggest that one possible mechanism of Enzastaurin activity is through 
inhibition of ABCB1 activity, either directly or indirectly through PKC-β, or a 
combination of both. In order to investigate whether Enzastaurin regulates PKC-β, 
thereby sensitizing cells, knock-down experiments should be performed. If this is 
true, knocking down PKC-β should sensitize resistant cells to Paclitaxel in a similar 
manner as Enzastaurin treatment. Similarly, over-expression of PKC-β in parental 













4.2. Aurora Kinase B expression levels as a biomarker for Paclitaxel-
sensitivity in basal-like breast cancer 
 
We have shown that there is a correlation between Paclitaxel-sensitivity, as 
determined by the EC50, and AURKB expression in basal-like, but not luminal-like, 
breast cancer. The correlation is significant in 8 different cell lines (p-value=0.0013, 
R2=0.8411) (Figure 3.27). Moreover, the Paclitaxel-resistant cells show down-
regulation of Aurora Kinase B in the presence of Paclitaxel, whereas when treated 
with Enzastaurin and Paclitaxel, Aurora B levels and Paclitaxel-sensitivity are 
restored (Figure 3.24). Also, siRNA-targeted knock-down of Aurora B confers 
resistance to Paclitaxel (parental cells) and combination treatment (resistant cells) 
(Figure 3.28). These results suggest that levels of Aurora Kinase B determine 
Paclitaxel-sensitivity.  
Paclitaxel is often used in first line treatment for TNBC in patients with primary 
breast cancer due to high positive response to neoadjuvant chemotherapy, but the 
relapse rate is high and the patients often suffer from metastatic and recurrent tumors. 
In these cases it is crucial to find the right treatment option as these tumors are high 
grade and progress quickly.  
We propose the use of Aurora B expression levels as a biomarker for Paclitaxel-
sensitivity. The expression levels of Aurora B in the tumor tissue vs. normal breast 
tissue can potentially determine the patient response rate to therapy containing 
Enzastaurin in combination with a Paclitaxel-containing chemotherapy regimen.  This 
is especially beneficial for patients, as it allows us to eliminate Paclitaxel-based 
therapies in patients with low levels of Aurora B, or to use Enzastaurin in 
combination with Paclitaxel to restore Aurora B levels. In addition, we found that 
Paclitaxel-resistant cells exhibit cross-resistance to other spindle poisons such as 
Vincristine, therefore the use of Aurora B as a biomarker and its implications in 
treatment can be extended to other mitotic spindle poisons. 
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4.3. Aurora Kinase B regulation 
 
We have shown that Aurora Kinase B plays an important role in Paclitaxel-resistance 
in our model of TNBC cell lines. Moreover, we showed that Aurora Kinase B levels 
negatively correlate with Paclitaxel-sensitivity in a number of basal, but not luminal, 
breast cancer cell lines. Our Paclitaxel-resistant cell lines have reduced expression 
levels of Aurora Kinase B as compared to the parental cell line and Aurora Kinase B 
knock-down inhibits Paclitaxel-induced cell death. This data suggests that modulation 
of Aurora Kinase B expression could influence sensitivity to Paclitaxel. There are a 
number of proteins which have an impact on Aurora Kinase B function through 
phosphorylation and dephosphorylation (Figure 4.3). The major players are INCENP, 
survivin and Borealin which are member of the Chromosomal Passenger Complex, 




The two major activators of Aurora Kinase B are TLK1 and Chk1, whose direct 
mechanism of Aurora activation are not clear. More interestingly, the two most 
important inhibitors of Aurora Kinase B are the protein phosphatases PP1 and PP2A. 
Figure 4.2 Major regulator of Aurora Kinase B 
Red arrows indicate protein phosphorylation events, whereas protein phosphatases are indicated 
in blue (Carmena et al., 2009).  
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They form complexes with Aurora Kinase B and negatively regulate its kinase 
function (Sugiyama et al., 2002).  
Although there are no reports of PKC directly regulating Aurora Kinase B function, it 
has been found that PKCs phosphorylate α-tubulin in the α/β-tubulin dimer which 
results in elongation of microtubules in human breast cells (De et al., 2014). In 
MB231 cells with high intrinsic PKC activity, this effect could be suppressed when 
the cells were treated with a PKC inhibitor. These results link PKC to microtubules 
and suggest that it could interact and influence Aurora Kinase B, however, they found 
that PKC-α is most likely responsible for α-tubulin phosphorylation, rather than PKC-
β. Moreover, one study found that PKC-δ plays a role in meiotic spindle organization 
in mouse oocytes and is associated with the meiotic spindle, thereby further 
strengthening the possibility of PKC-β regulating Aurora Kinase B function through 
its association with the mitotic spindle. 
It is not clear whether the increase in Aurora B levels observed in the resistant cell 
lines after sensitization with Enzastaurin is the reason for the cells being sensitized to 










4.4. Mcl-1 degradation by GSK3β in the presence of Paclitaxel 
 
Mcl-1 stability is primarily regulated by GSK3β, as it can phosphorylate Mcl-1 at 
Ser155, Ser159, and Thr163 (Ding et al., 2007, Maurer et al., 2006). Once Mcl-1 is 
phosphorylated, it can be ubiquitinated and will subsequently undergo proteasome-
mediated degradation. Three E3 ubiquitin ligases have been identified which 
ubiquitinate Mcl-1: 1) Mule was the first ligase identified to ubiquitinate Mcl-1 
(Zhong et al., 2005); 2) β-TrCP ubiquitinates and leads to Mcl-1 degradation which is 
dependent on Mcl-1 phosphorylation by GSK3β (Ding et al., 2007); 3) FBW7 is a E3 
ubiquitin ligase which ubiquitinates Mcl-1 in a GSK3β phosphorylation-dependent 
manner (Wertz et al., 2011). Mcl-1 down-regulation is crucial for apoptosis induced 
by mitotic arrest after treatment with spindle poisons. It was shown that inactivation 
of FBW7 could increase Mcl-1 levels and resistance to Taxol and Vincristine in 
ovarian cancer cell lines. Moreover, FBW7-depleted cells showed an increase in cells 
undergoing mitotic slippage and a decrease in cells undergoing apoptosis, when 
treated with Taxol or Vincristine.  
In agreement with the reports demonstrating the importance of GSK3β in inducing 
apoptosis through Mcl-1 upon Paclitaxel treatment, our Paclitaxel-resistant cell lines 
show increased levels of Serine 9 phosphorylation of GSK3β, the inhibitory 
phosphorylation site. Upon treatment with Enzastaurin, GSK3βSer9 levels are 
completely depleted, however, this only leads to Mcl-1 degradation in the presence of 
Paclitaxel. One possible reason is that Mcl-1 requires a priming phosphorylation in 
order to be recognized by GSK3β as a substrate (Morel et al., 2009). It was shown 
that upon cellular stress, the c-Jun-terminal protein kinase (JNK) phosphorylates Mcl-
1 on Thr144, which acts as a priming phosphorylation so that GSK3β can then 
phosphorylate Mcl-1 at its own phosphorylation site. It has been shown that 
Paclitaxel treatment activates JNK (Wang et al., 1999) and that inhibition of JNK 
decreases Paclitaxel-induced apoptosis without changing the cell cycle profile (Wang 
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et al., 2006). This may explain why only in the combination treatment of Enzastaurin 
+ Paclitaxel of our Paclitaxel-resistant cell lines, but not in the single treatment with 
Enzastaurin alone, Mcl-1 undergoes degradation which subsequently leads to 
apoptosis.  
On the other hand, prolonged mitotic arrest leads to Mcl-1 destruction (Harley et al., 
2010), which leads to activation of BAX and BAK and subsequently mitochondrial 
outer membrane permeabilization and activation of the caspase cascade and induction 
of apoptosis (Youle and Strasser, 2008). Mcl-1 degradation upon mitotic arrest is 
crucial for the induction of apoptosis. Degradation is regulated by the APC/CCdc20 
complex, a multi-component ubiquitin ligase which is active during mitosis. It has 
been shown that phosphorylation of Mcl-1 at Thr92 is mediated by Cdk1/cyclin-B 
upon mitotic arrest which then leads to its proteolytic destruction by APC/CCdc20. 
During mitosis, Mcl-1 levels gradually decrease and when mitotic arrest is too long 
and Mcl-1 levels are too low, the cells will undergo apoptosis. Therefore, Mcl-1 
degradation upon combination treatment in our resistant cells is possibly a result of 
prolonged mitotic arrest. 
These are two possible mechanisms of Mcl-1 degradation during re-sensitization of 
Paclitaxel-resistant cells with Enzastaurin. At this point it is unclear if either of the 
two possible mechanisms, a combination of both, or even a different mechanism is 
responsible for Mcl-1 degradation in the resistant cell lines upon re-sensitization. 
Either way, to examine whether Mcl-1 degradation is required for sensitization of 
resistant cell lines, Mcl-1 over-expression should be able to block the effect of 
Enzastaurin and rescue the sensitization effect of Enzastaurin with Paclitaxel in the 



































In this study we developed an in vitro model of Paclitaxel resistance in Triple 
Negative Breast Cancer by treating the TNBC cell lines, SUM159PT and MB231, 
over a long period of time with increasing concentrations of Paclitaxel and 
maintaining them in medium containing Paclitaxel. The stable cell lines exhibited 
EC50 values for Paclitaxel which were approximately 1000-fold and 300-fold higher 
than their parental counterparts in SUM159PT and MB231, respectively. Gene 
expression profiling showed that pathways for cell viability, cell survival, 
proliferation, invasion, migration and microtubule dynamics were more highly 
activated, whereas cell death and apoptotic pathways were less activated in the 
resistant compared to the parental cell lines. Although, according to IPA analysis, the 
network with the highest score has the NF-κB complex at its core, NF-κB inhibitors 
were not selective for the resistant over the parental cell lines. This shows that the 
NF-κB pathway is important in both resistant and sensitive cells.   
In order to determine pathways which play a crucial role in resistance to Paclitaxel, 
we performed a pharmacological screen with 180 small molecule inhibitors targeting 
various kinases. The screen revealed PKC-β inhibitors to be effective in sensitizing 
resistant cells to Paclitaxel. In the presence of Paclitaxel, the PKC-β inhibitor 
Enzastaurin reduces cell viability, colony formation and induces cell death. We found 
that the resistant cell lines show reduced levels of Aurora Kinase B, a member of the 
spindle assembly checkpoint which plays an important role in Paclitaxel-induced cell 
death (Sudo et al., 2004). Although the mechanism of sensitization is not entirely 
clear, Enzastaurin restores Aurora Kinase B levels in the resistant cell lines, thereby 
reinstating mitotic arrest and subsequent apoptosis when treated with Paclitaxel. 
Interestingly, we found an inverse correlation between Aurora Kinase B and 
Paclitaxel-sensitivity in basal-like, but not luminal, breast cancer cell lines, which 
reinforces the importance of Aurora Kinase B in Paclitaxel-induced cell death. 
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Knocking-down Aurora Kinase B in the parental Paclitaxel-sensitive cell lines using 
siRNA renders them more resistant to Paclitaxel treatment, whereas Aurora Kinase B 
knock-down in the resistant cell lines inhibits reduction of cell viability upon 
combination treatment of Paclitaxel with Enzastaurin. This shows that Aurora Kinase, 
indeed, plays an important role in Paclitaxel-sensitivity. Moreover, knock-down 
inhibited mitotic arrest in the presence of Paclitaxel in the parental and Enzastaurin-
treated resistant cell lines.  
In summary, a kinase inhibitor screen identified PKC-β inhibitors which can re-
















5.2 Significance of findings and future prospects 
 
TNBC is the most aggressive subtype of breast cancer. The mainstay of treatment is 
chemotherapy which shows positive results in a neoadjuvant setting, however, 
approximately 70% of patients will relapse and present with recurrent disease, often 
accompanied by chemo-resistance and poor survival outcome. Based on the results 
from this study, the PKC-β inhibitor Enzastaurin can potentially be used in the 
treatment of TNBC patients suffering from recurrent and metastatic disease. 
Especially since recurrent disease is a major issue in the treatment of these patients. 
Despite the fact that clinical trials with Enzastaurin and Paclitaxel have proved that it 
is safe when administered in combination with chemotherapeutics, the results 
regarding improvement of patient survival have been inconclusive. A phase II 
double-blind study which was conducted with and without Enzastaurin in 
combination with Paclitaxel and Carboplatin as first-line treatment in advanced 
ovarian cancer showed a slight increase in PFS for patients which received 
Enzastaurin, however it was not significant (Vergote et al., 2013). 
To provide proof of concept, in vivo studies using xenograft models should be 
conducted. We propose to generate an in vivo mouse model of Paclitaxel resistance. 
For this, chemo-sensitive cells are injected orthotopically into the mammary fat pad 
of mice, once the tumors have grown they will be treated with Paclitaxel until they 
regress. The mice are then monitored for recurrence (approximately 3-4 months) and 
subsequently randomized into 4 different treatment groups: Control, Paclitaxel, 
Enzastaurin, and combination of Paclitaxel with Enzastaurin. If it is true that 
Enzastaurin can sensitize resistant cells to Paclitaxel, then mice in the combination 
treatment group should have significant reduction of tumor size and increased 
survival advantage compared to mice in other treatment groups. The tumors of mice 
in the control, Paclitaxel, and Enzastaurin treatment groups, on the other hand, should 
continue to grow.  
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As we have shown earlier, the Paclitaxel-resistant cell lines we generated show 
resistance to other chemotherapeutic compounds: the spindle poison Vincristine; and 
Adriamycin. Interestingly, Enzastaurin can greatly sensitize resistant cells to 
Vincristine but to a much lesser extent to Adriamycin. This suggests that the 
mechanism of sensitization by Enzastaurin is specific to microtubule-disrupting 
drugs. Similar to the Paclitaxel resistance mouse model, in vivo mouse models of 
Vincristine and Adriamycin resistance should be established to give proof-of-concept 
that Enzastaurin can sensitize to Vincristine and Adriamycin. This would greatly 
enhance the significance of using Enzastaurin in treating recurrent and chemo-
resistant TNBC patients, as Vincrstine and Adriamycin are 2 drugs which are also 
often used in first line treatment of TNBC tumors. More importantly, since the 
sensitization effect is stronger for Vincristine, Enzastaurin can potentially be used to 
treat cancer recurrence in patients suffering from acute leukemia, Hodgkin’s and 
Non-Hodgkin’s lymphoma, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, 
multiple myeloma, thyroid cancer, brain tumors since Vincristine is one of the main 
drugs used in first-line treatment of these patients. 
To measure the true effect of Enzastaurin in increasing Paclitaxel-sensitivity, a 
clinical trial should be conducted with patients suffering from residual and recurrent 
disease and that have previously been treated with a combination of chemotherapeutic 
agents containing Paclitaxel. These cancers are more likely to have developed 
mechanisms of Paclitaxel resistance and will respond to treatments comprising of 
Paclitaxel and Enzastaurin. 
Furthermore, the mechanism of re-sensitization by Enzastaurin needs to be studied in 
more detail. Although Enzastaurin was originally developed as a PKC-β inhibitor, it 
has been shown to have other targets as well, such as ABCB1 (Michaelis et al., 2015). 
Moreover, since the various PKC isoforms are structurally similar, we need to 
identify the specific isoforms inhibited by Enzastaurin. Therefore, we need to 
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specifically knock-out the PKC-β isoform and determine whether this can sensitize 
our Paclitaxel-resistant cell lines, similar to Enzastaurin treatment. CRISPR can be 
used to knock-out PRKCB, rather than just performing a gene knock-down, which 
does not ensure complete elimination of gene function. This is important since 
residual gene expression can often be enough to induce down-stream signaling and 
will not give us correct information of the function PKC-β in Paclitaxel-resistance.  
In addition, as this study shows that there is a negative correlation between Aurora 
Kinase B expression and Paclitaxel-sensitivity, Aurora Kinase B levels should be 
monitored in patient tumor cells during the course of diagnosis and treatment. The 
expression of Aurora Kinase B in the tumor tissue and the tissue surrounding the 
tumor should be measured at the time of diagnosis and taken as a reference should the 
patient present himself with residual or recurrent disease. If the levels of Aurora 
Kinase B have decreased, it can be considered to treat the patient with a combination 
of Paclitaxel and Enzastaurin. 
Moreover, the strategy of restoring Aurora Kinase B expression to sensitize resistant 
cancer cells can be applied to other cancers which show a reduction in Aurora Kinase 
B levels as the disease progresses. Therefore, this study not only benefits TNBC 
breast cancer patients but those presenting with different types of chemo-resistant, 
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